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ABSTRACT 
 
Ayodele Gomih: The Role of HPV and DNA Methylation in the Development of Precancerous Cervical 
Lesions  
(Under the direction of Jennifer S. Smith) 
 
Biological factors associated with cervical intraepithelial neoplasia (CIN) development may be 
utilized to improve the efficiency of cervical cancer screening. The present study examined human 
papillomavirus (HPV) genotypes and DNA methylation of imprinted genes in a survival analysis, using 
two endpoints: CIN1 regression and progression to CIN2+. 
The CIN Cohort Study (CINCS) was conducted at 10 Duke University clinics in North Carolina. 
Women ages 18-65 years with enrollment colposcopies following an abnormal Pap test had follow-up 
cytology/histology for 3 years with up to 5 visits. DNA was extracted from exfoliated cervical cells for 
methylation at differentially methylated regions (DMR) of imprinted genes and for HPV genotyping. 
Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox regression models to 
estimate the association between aberrant methylation and CIN1 regression (normal epithelia) versus 
persistence/progression (CIN1+). HRs/95% CIs were estimated to quantify genotype-specific risk of 
progression to CIN2+. 
Of 1303 participants, 472 normal/CIN1 cases with HPV data and 151 CIN1 cases with 
HPV/methylation data were included in the prospective analyses. In the analysis of genotype-specific risk 
of progression, hrHPV-66/51/16 were most prevalent in multiple-type infections among 364 HPV-
unvaccinated women; 16/52/35 in single-type. Among 108 HPV-vaccinated women, hrHPV-66/39/51 
were most prevalent in multiple-type infections; hrHPV-51/66/52/58 in single-type. Over 3 years, there 
were CIN2+ events (11%;38% normal;62% in CIN1). HrHPV-16/51 had a 3-fold risk of progression 
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(HR=3.2,95% CI=1.5-7.2;HR=3.2,95% CI=1.3-7.6) versus non-16/51 infections. HPV-16/51 were most 
predictive of progression to CIN2+.  
In the CIN1 regression analysis, one-third regressed to normal epithelium (n=53;35.1%). Median 
time-to-regression was 12.6 months (range:4.5-24.0). The probability of CIN1 regression was negatively 
correlated with increased methylation at IGF2AS CpG 5 (HR=0.42,95% CI=0.23-0.77;p=0.005) and 
PEG10 DMR (HR=0.78,95% CI=0.63-0.96;p=0.02).  
HPV-51 was positively associated with increased risk of progression; aberrant methylation of 
PEG10/IGF2AS reduced the likelihood of CIN1 regression. PEG10/IGF2AS methylation may serve as 
potential biomarkers for screening, given further characterization of tumorigenesis pathways related to 
dysregulation of imprinted gene expression. HPV-51 may be useful for CIN2+ risk stratification. If 
confirmed in other populations, implementation of these novel biomarkers may improve LSIL 
management and patient care. 
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CHAPTER ONE: STATEMENT OF SPECIFIC AIMS 
 
Cervical cancer is a highly preventable cancer by screening. In the United States, current screening 
guidelines recommend the use of high-risk human papillomavirus (HPV) detection with liquid-based 
cytology testing for women between the ages of 30 and 65 years for detection of high-grade cervical 
intraepithelial neoplasia (CIN), the precursor of cervical cancer [1]. All low-grade cytology and HPV-
16/18-positive/cytology-negative cases are referred for immediate colposcopy [1]. The role of other non-
16/18, high-risk HPV genotypes in clinical management of cervical lesions has not been well 
characterized. The role of epigenetics in cervical carcinogenesis— specifically, DNA methylation of 
imprinted genes— may also serve as a potential biomarker for CIN progression. Novel biomarkers in 
screening can help further stratify risk of lesion progression and reduce the number of colposcopy 
referrals, improving patient care and quality. To identify potential biomarkers in the development of CIN, 
the following research aims were addressed: 
 
AIM 1: To examine the association between HPV infection by genotype and the progression of low-
grade cervical epithelial neoplasia (CIN1 to CIN2+) or persistence (CIN1 to CIN1) of precancerous 
cervical lesions in the Cervical Intraepithelial Neoplasia Cohort Study (CINCS). 
 
AIM 2: To examine the impact of DNA methylation of imprinted genes on the regression of low-grade 
precancerous lesions (CIN1 to normal) in the Cervical Intraepithelial Neoplasia Cohort Study (CINCS). 
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
Burden of human papillomavirus and cervical cancer  
Human papillomavirus (HPV) is an extremely common sexually transmitted infection (STI), 
affecting nearly 79 million people in the United States (US), with approximately 14 million new 
infections each year [2]. Of 100 known HPV genotypes, 40 can affect the genital area [3]. HPV infection 
is more prevalent among Black and Hispanics compared to Whites, especially in low-income populations 
[4, 5]. 
HPV infection is a necessary cause in cervical cancer development [6]. Fourteen high-risk 
oncogenic HPV types have been identified as the main etiologic agents in cervical cancer, in which types 
16 and 18 alone cause 70% of all cases [7]. There are over 12,000 new HPV-related cervical cancer cases 
in the US each year [8]. In North America, 3 women per 100,000 die from cancer of the cervix [8].  
The highest rates of cervical cancer in the US occur in the South; the incidence in North Carolina is 
comparable to overall cancer incidence nationwide (age-adjusted rate: 7.4 per 100,000). Furthermore, 
cervical cancer disproportionately affects racial and ethnic minorities relative Whites in the US, with 
higher prevalence of both HPV infection and cervical cancer in Blacks than Whites [4, 5]. While there are 
comparable screening rates, both incidence and mortality is higher among Blacks and Hispanics [9-11]. In 
NC, cancer incidence is more than 60% higher in Blacks and Hispanic women compared to White women 
[9, 12]. 
HPV and Cervical Cancer Screening/Prevention 
Methods for Cervical Cancer Screening  
 
Early detection and treatment of precursor cervical intraepithelial neoplasia (CIN) is an effective 
strategy to prevent cervical cancer and related deaths. Screening methods to identify CIN and invasive 
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cervical cancer (ICC) have been available for more than three decades. The Papanicolaou test, best known 
as a Pap smear test, is the original cytology-based method for detection of abnormal cervical cells. 
Developed in 1941 by Dr. George Papanicolaou, the Pap test allowed for the identification of 
precancerous and cancerous cells in cytology samples from vaginal aspirates [13]. The American Cancer 
Society endorsed the use of Pap tests in formal cervical screening settings in 1957.  
The implementation of cytology-based screening and national screening and management 
guidelines designed by the American Society for Colposcopy and Cervical Pathology (ASCCP) have led 
to substantial decreases in the incidence and mortality of ICC in the United States [13, 14]. However, 
conventional Pap tests have variable sensitivity to detected high grade cervical lesions due to variation in 
sample and slide preparation [13, 15, 16]. Liquid-based cytology (LBC) screening methods were 
developed to improve clinical performance within the past 17 years. In the US, 90% of Pap tests used to 
screen for cervical lesions are LBC-based methods such as ThinPrep (Cytyc Corp, Marlborough, MA), 
preferred over conventional Pap smear tests [13].  
Overall, Pap tests have high specificity to distinguish non-diseased (>90%)[17]. However, 
detection by cytology alone requires a series of repeated Pap tests and/or unnecessary referral to 
colposcopy and potential surgical excision [15, 18-21]. While women with low-grade CIN— especially 
young women— are more likely to regress, women who have persistent infection with high-risk HPV 
(hrHPV) genotypes can lead to persistent dysplasia and progression to ICC [22]. Evidence demonstrates 
that high-risk HPV infection can better predict development of CIN3 and ICC [22, 23]. As a result, recent 
age-specific recommendations include the use of HPV testing in conjunction with cytology-based 
screening for women over 30 years of age [22]. The Food and Drug Administration (FDA) approved the 
use of the cobas assay (Roche Diagnostics, Indianapolis, IN) for routine screening [22, 24]. Other 
companies are amidst developing and testing of other high-risk genotyping assays, such as APTIMA 
(Hologic, Marlborough, MA) and BD (Franklin Lakes, NJ). 
Primary screening with HPV is currently recommended in the US for clinical practice as a 
method of screening triage. The ASCCP currently recommend that women who test positive for HPV-
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16/18 are referred for immediate colposcopy, whereas positive tests for the other 12 hrHPV genotypes are 
referred for cytology and HPV-negative women follow routine screening guidelines[1, 24]. While HPV 
co-testing has increased the ability to detect high-risk women, improving the efficacy of cervical 
screening methods can reduce the number of unnecessary screenings and associated cost, patient anxiety 
and issues with low adherence to follow-up recommendations. Therefore, it is important to further explore 
the impact of other oncogenic HPV types among women who have negative cytology and low-grade 
lesions that are more likely to progress to high-grade cervical lesions. With a better understanding of the 
sociodemographic determinants of CIN and ICC, cancer screening and management efforts may better 
address those groups at highest risk.   
Additionally, recognizing the extent to which other oncogenic HPV (e.g. non-16/18) types lead to 
CIN progression is crucial to current prevention strategies. Further research in HPV typing in 
carcinogenesis can inform vaccine development and improve coverage in preventing future transmission. 
Hence, this dissertation research aimed to determine whether infection with a particular HPV type varies 
the rate of progression to high-grade CIN or cervical cancer, and determine whether these rates differ 
among women of different racial/ethnic backgrounds in a multiracial cohort. 
 
Epigenetics and Cervical Tumorigenesis 
Epigenetics and Cancer/Disease  
Genetic research has ensued for years in order to understand potential targets for disease prevention and 
clinical interventions. However, epigenetics of cancer has become an increasingly popular topic of 
interest for researchers. Epigenetics— the control of gene expression by external chemical 
modifications— may alter biological pathways involved in tumorigenesis [25]. Such alterations can 
include DNA methylation and chromatin modification, both of which can control gene activity and affect 
gene expression and activation in cells [26]. DNA methylation has been well researched, especially in the 
context of human cancers, making them probable candidates for targeted therapies and screening markers.  
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DNA methylation occurs at cytosine-phosphate-guanine (CpG) sites, which are concentrated in 
regions throughout the genome in “islands” [27]. These CpG rich regions are not typically methylated, 
and are situated at the 5’ end of regulatory regions for several genes, at promoters, that control gene 
expression [27]. Unmethylated CpG islands at gene promoters allow for the binding of transcription 
machinery and transcription of DNA into mRNA[28] (Figure 2.1). However, methylation of the promoter 
prevents transcription and subsequent gene expression[28] (Figure 2.1). 
 
Figure 2.1 Methylation at CpG islands at promoter regions controls gene expression [29] 
 
Genomic Imprinting Loss of Imprinting and Cancer 
An alternative mechanism of interest for determining the extent to which epigenetic changes 
impacts tumorigenesis is the role of DNA methylation in imprinted gene networks. Unlike autosomal 
genes that are dually expressed from both the maternally- and paternally-derived chromosomal alleles, 
expression of genomically imprinted genes are determined by one parent and epigenetically marked to 
express only one allele while the other allele is transcriptionally silenced [26, 30]. Aberrant methylation at 
regulatory elements of imprinted genes can either silence the only active allele (loss of imprinting) or 
reactivate the normally silent allele (bilallelic expression), both nullifying normal gene function.  
 6
Imprinted genes typically exist in clusters, thus share common regulatory elements. These 
elements include differentially methylated regions (DMRs), which can be intergenic or intragenic and are 
critical in tissue-specific gene expression [31-33]. In mice, Igf2, H19, Zac, Mest, Peg3, Dlk1, Meg3, 
Grb10, Ndn, Cdkn1c and SLC38a4 appear to exhibit coordinated repression with growth deceleration 
[34]. In vitro experiments also showed genetic induction of several imprinted genes on different 
chromosomes related to the overexpression of another gene as a result of aberrant methylation [35]. As 
imprinted genes are susceptible to deregulation, they should be strongly considered as key mediators in 
cancer development. 
Their role in cancer was first supported by their role in Beckwith-Wiedemann syndrome (BWS) 
caused by defects in imprinting on chromosome 15 with affected individuals predisposed to Wilms tumor 
and hepatoblastoma [26, 36]. Loss of imprinting also has occurred colorectal cancer with insulin growth 
factor-2 or IGF2 [37].  
DNA Methylation Markers for Cervical Dysplasia  
Because cancer progression occurs through the loss and/or gain of genetic function, genetic and 
epigenetic biomarkers for CIN2+ have received considerable attention in research aimed to distinguish 
women with benign infection from those requiring treatment over the past 15 years. Specifically, DNA 
methylation can influence transcription and expression of genetic factors involved in cervical cancer 
development without directly altering the underlying gene’s DNA sequence [25]. 
One proposed mechanism for CIN progression involves epigenetic modifications at gene 
promoter CpG islands that impact transcription, inhibiting expression of tumor suppressor genes. 
However, aberrant methylation of promoter regions has not been strongly associated with CIN 
progression [38] and data is inconclusive on whether any specific methylation markers can be utilized as 
markers for screening[31, 38-40]. The role of methylation in HPV’s carcinogenicity has been explored as 
a potential marker of cervical progression, DNA methylation that alter the expression of critical genes that 
can either inhibit or promote cervical carcinogenesis[31, 40]. Methylation of high-risk HPV genomes has 
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also been assessed as a potential pathway in the progression of cervical dysplasia [31, 40]. Specifically, 
integration of HPV-16 into the host genome has resulted in the expression of E6/E7 oncoprotein genes 
that in turn, results in overexpression of p53 and PBR tumor suppressing genes (citation).  
Hypermethylation of HPV-16 E6 and E7 oncogenes (which promote HPV virulence) may cause binding 
of DNA transcription factors that influence cancer development [31]. Further studies in humans have 
demonstrated differential changes in methylation at imprinting centers among women who had cervical 
intraepithelial and invasive cervical cancer. An analysis of publicly available microarray data found that 
expression of imprinted genes differed between specimens from ICCs compared to normal cervical 
epithelium (NCE) specimen (Table 2.1). 
Table 2. 1 DNA Methylation of Imprinted Genes in Cancerous vs. Normal Cervical Tissue 
(Hoyo/Murphy Group) 
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For example, paternally-expressed SNRPN/SNURF genes were suppressed compared to NCE samples; 
similarly, paternally-expressed PEG10 was overexpressed in comparison to normal cases. This finding 
supports that the expression profile of imprinted genes differs in cervical cancer cases compared to 
normal cases and thus these genes warrant further research in CIN progression. 
Influence of HPV and External Factors on DNA Methylation and Cancer 
Epigenetic changes to the host genome are typically attributed to external forces, such as the 
environment and lifestyle behaviors. Cofactors such as smoking, high parity, and oral contraceptive use 
may influence these epigenetic changes that lead to progression of cervical dysplasia. It is established 
that, in addition to persistent high-risk HPV infection, cigarette smoking, long term oral contraceptive 
use, and high parity are risk factors for cervical cancer and CIN [20]. These identified factors may also 
influence DNA methylation and therefore lead to loss of imprinting and potential functionality of both 
growth factors and tumor suppressor genes. 
The relationship between DNA methylation and HPV infection, as previously described, has been 
explored in the context of mainly high-risk HPV types 16 and 18. To our knowledge, no studies have 
examined aberrant methylation patterns of imprinted genes within other high-risk HPV types. In addition, 
while smoking is known to be associated with cervical cancer and many other cancer outcomes, the 
mechanism for smoking’s impact on CIN is not well understood. Smoking does not appear to have an 
effect on the clearance or persistence of HPV infection, suggesting that the effect of smoking may be 
independent of HPV infection in the process of cervical cancer progression [41-43]. Further, it is 
inconclusive whether smoking increases the risk of HPV infection by lowering immunity and antibody 
levels [44, 45]. Still, smoking appears to influence methylation of IGF2 or Insulin-like Growth Factor 2, 
leading to loss of imprinting of IGF2/H19 [46]. This finding is of great importance, as loss of imprinting 
of IGF2/H19 gene complex occurs in 58% of cervical cancers [47]. Hence, additional research is required 
to characterize the roles of both HPV types and smoking in the methylation of imprinted genes. 
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Thus, differentiation of CIN cases that are more likely to progress or regress using epigenetic 
biomarkers requires further investigation. Ultimately, the findings of this research can improve the 
efficiency of cervical screening and optimize clinical management of CIN, reducing unnecessary testing 
and treatment of affected women. 
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CHAPTER THREE: RESEARCH PLAN AND METHODS 
Study Population  
The Cervical Intraepithelial Neoplasia Cohort Study (CINCS) is a 3-year prospective study that 
enrolled participants between 2010 to 2014 to determine whether epigenetic deregulation of known 
imprinted genes can be used to distinguish women more likely to progress to CIN2+.  
The cohort includes 1303 women aged 18 years and older with abnormal cytology attending 10 
Duke University and Duke Primary Care (DPC) clinics in Durham County, North Carolina. North 
Carolina is located in southeastern region of the USA, where cervical cancer is most prevalent.  
Recruitment and Study Follow-Up 
Recruitment at the clinics 
 
Potential participants included women who were referred for colposcopy following an abnormal 
cervical screening test. Prospective participants were identified by their physicians two weeks prior to a 
scheduled colposcopy appointment through the electronic clinic appointment logs of the Duke University 
and community clinics. The attending physicians provided signed letters of invitation for study 
participation to mail to potential study participants prior to the colposcopy. Study invitation letters 
explained the broad goals of the study and expectations of participants. The colposcopy patients were 
instructed to call a toll-free number to register their intent to decline participation. During the scheduled 
colposcopy appointment visit, the recruiting interviewer solicited participation directly from the 
participant and administered the informed consent process. After consent, participants were given a 
standardized questionnaire to ascertain demographic and clinical information. Further information was 
collected on cervical dysplasia diagnosis through histopathological confirmation typically two weeks after 
the colposcopy visit. 
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Follow up of women after abnormal cytology diagnosis  
Study participants attended a clinic visit approximately every 6 months to 1 year for 3 years, 
following clinical practice guidelines for management of CIN (Figure 1). At each visit, clinic physicians 
conducted a cervical examination to ascertain information on any cytological/histological changes. A 
follow-up questionnaire was administered to ascertain information on any behavioral and clinical 
characteristics of the participant since enrollment. 
 
Figure 3. 1 CINCS Study Visit Flow Chart 
 
Eligibility criteria 
To be eligible to participate in CINCS overall, women were new visitors to the colposcopy clinic 
with histopathology results from a colposcopy-directed biopsy (inclusive of endocervical curettage) 
following an abnormal Pap test. Because most CIN is commonly transient in younger women (<21 years 
old) [22], enrollees ranged in age from 21 to 79 years. Participants were English or Spanish-speakers and 
mentally competent to give informed consent. Women who had treatment for cervical lesions (e.g. cold 
knife conization, loop electrosurgical excision procedure, hysterectomy) were excluded from the study. 
Women were further excluded if they did not intend to receive follow-up care in one of the 10 DPC 
clinics or moved out of the area for other reasons. 
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Eligibility criteria for Aim 1 
Women were required to have histopathologically-confirmed diagnosis of normal epithelial/CIN1 
at their enrollment visit. Participants must have attended at least one follow-up visit following enrollment, 
at which they received either a Pap test and/or colposcopy with cervical biopsy and/or endocervical 
curettage. Participants without data on HPV status were excluded. 
 
Eligibility criteria for Aim 2 
Participants with a histopathology-confirmed CIN1 diagnosis at the enrollment visit were 
included. at their enrollment visit. Participants must have attended at least one follow-up visit following 
enrollment, at which they received either a Pap test and/or colposcopy with cervical biopsy and/or 
endocervical curettage. Participants without data on HPV status or imprinted gene methylation were 
excluded. 
 
Data Collection 
Cervical Cytology & Histology Specimens 
During the Pap test at baseline, the clinic physician utilized a spatula and cytobrush to obtain 
exfoliated cervical cells. Cervical specimens were suspended in a Thinprep vial containing proprietary 
fluid with at least 50% methanol (Cytyc®, Malborough, MA, USA) for cytology confirmation. Following 
abnormal cytology results, clinic physicians performed colposcopy-directed biopsy at baseline. 
Information on cytology and lesion morphology, including size and location, were abstracted from patient 
medical records. All specimens were tested for adequacy using the 2012 ASCCP guidelines. The 
specimens were stored at 4°C prior to HPV testing.  
All Pap test results were classified as one of the following by a pathologist according to 2012 
Bethesda system [48]: i) negative/normal cytology; ii) low-grade squamous intraepithelial lesion (LSIL); 
iii) atypical squamous cells of undetermined significance (ASCUS); iv) atypical glandular cells of 
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undetermined significance (AGUS); v) high-grade squamous intraepithelial lesion (HSIL); vi) low-grade 
squamous intraepithelial lesion, cannot exclude HSIL (LSIL-H); or vii) atypical squamous cells cannot 
exclude HSIL (ASC-H).  
To ascertain the presence of CIN, cervical biopsies were adjudicated by a clinical pathologist. 
CIN diagnoses were classified as follows: i) CIN-1; ii) CIN-2; iii) CIN-2/3; iv) CIN-3; or v) ICC. 
 
HPV DNA testing 
HPV typology was assessed using excess cervical tissue obtained from the enrollment biopsy. 
ThinPrep® specimens and homogenized aliquoted biopsies were collected during the same baseline visit 
and shipped to the University of Hawaii Cancer Center. Following DNA extraction, PGMY09/PGMY11 
primers [49, 50] were used in PCR to target a 450-bp region of the HPV L1 genome. Amplification of the 
human β-globin gene was included as an internal control for sample sufficiency. HPV-positive specimens 
were subsequently genotyped by using the HPV Linear Array® (Roche Diagnostics, Branchburg, NJ, 
USA). This assay is designed to detect 14 high-risk HPV types— 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66 and 68— and low-risk HPV types— 6, 11, 26, 40, 42, 53, 54, 61, 62, 64, 67, 69, 70, 71, 72, 73, 
81, 82, 83, 84.  
 
DNA Methylation 
Nucleic acid extraction 
At the enrollment of all participants, a 10ml blood sample in an EDTA tube was collected for 
DNA and plasma. The phlebotomy laboratory run by the Duke Clinical Research Unit (DCRU) collected 
peripheral blood for methylation assays. Peripheral blood DNA was extracted from buffy coat using 
PureGene Reagents (Qiagen) according to the manufacturer’s instructions. RNA and DNA from the 
ThinPrep cell pellet were extracted using the protocol for simultaneous nucleic acid extraction provided 
by Teltest for their RNA Stat60 and DNA Stat60 reagents. Nucleic acids will be aliquoted, barcoded, and 
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stored at -80ºC until required. Methylation and host genetic analyses were performed by the Duke 
Epigenetics Group led by Drs. Murphy and Jirtle within their respective laboratories. 
 
Methylation analysis 
DNA methylation was measured at differentially methylated regions (DMRs) that regulate the imprinted 
genes IGF2 AS, IGF2/H19, PEG1/MEST, KV DMR, DLK1/MEG3, PLAG1/HYMA1, PEG10 and PEG3 
DMR using the Sequenom MassARRAY platform with EpiTYPER analysis software. Primers were 
designed with EpiDesigner software which designs primers complementary to bisulfite treated DNA in 
regions without CpG nucleotides; it then adds a T7 promoter site to all forward primers (Table 3.1).  
 
Table 3. 1 Imprinted Gene Primers used in Sequenom analysis for DNA methylation 
 
After PCR amplification, unincorporated nucleotides were removed with shrimp alkaline phosphatase, 
and the PCR products were transcribed by T7 RNA & DNA polymerase with simultaneous cleavage by 
RNase A. Including either dCTP or dTTP in the transcription reaction restricts cleavage by RNase A to 
positions immediately 3’ of thymine or cytosine residues, respectively. The fragmented transcripts were 
spotted onto SpectroCHIPS for mass spectrometry analysis on the MassARRAY instrument. The 
fragments were identified by matching the molecular mass of detected particles to that expected from 
Gene Primer Seq. Chr. Start End
H19-IGF2 aggaagagagTATTTTGAGGTTTTGGGGGATATTA 11 2130112 2130388
cagtaatacgactcactatagggagaaggctCTCCCTCAACAAAAACTAACAAATC
MESTIT1, MEST aggaagagagGGGTTTAGAGGTATAAGAAAGAGGG 7 130130648 130131063
cagtaatacgactcactatagggagaaggctTTTCTAAAAACAACCAAACCCCTAC
KvDMR aggaagagagTTTGGTAGGATTTTGTTGAGGAGTTTT 11 2721161 2721464
cagtaatacgactcactatagggagaaggctCTCACACCCAACCAATACCTCATAC 
MEG3 aggaagagagTTGTGATAAGGTTAGTGAGGGGTTA 14 101293947 101294390
cagtaatacgactcactatagggagaaggctCCAACCAAAACCCACCTATAACTAC
HYMAI, ZAC aggaagagagGAAAAAGTTTGTTTTAAGTAATAATGGGAT 6 144328445 144328885
cagtaatacgactcactatagggagaaggctAAAAAACCAAAACCTCAATAAAACC
PEG10 aggaagagagAGGTGTGGGATTTTATTTTTTTTGT 7 94285845 94286061
cagtaatacgactcactatagggagaaggctCAAACCTTTAAAACTTAATTTCCCC
PEG3, ZIM2 aggaagagagTATTGGGTGTTATTTTTTATGAGGG 19 57350715 57351051
cagtaatacgactcactatagggagaaggctTCTACTACCAACCAACCAAAACAAC
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analysis of the reference sequence. The analysis software compares the relative amounts of methylated 
forms of each predicted fragment to quantify the methylated fraction.  
 
Analytic Methods 
Aim 1: To examine the association between HPV genotypes and the progression to CIN2+ among normal 
and low-grade CIN in the CINCS.  
a. Determine whether progression to CIN2+ varies by individual HPV status (positivity) or 
HPV type-grouping (high-risk HPV types compared to infection with low-risk HPV types). 
b. Assess whether the association between HPV infection (positive vs. negative; high-risk vs. 
low-risk) and the progression to CIN2+ is modified by race, smoking, parity, or oral 
contraceptive use. 
Time-to-progression analysis with Cox proportional hazards were used to examine the 
relationship between HPV genotypes/risk group and progression to CIN2+. CIN outcome at follow-up 
was dichotomized as progression vs. persistence/regression. 
We defined progression as a more severe CIN score (CIN-2+) at a follow-up visit; persistence as retention 
of the same diagnosis at a follow-up visit (CIN-1); and regression as a less severe CIN diagnosis. 
Cytology results were used if the participants had missing histology data as a result of conservative 
clinical practice. A description of the outcome classification is described in Tables 3.2.1-3.2.4. 
 
Table 3.2. 1 Progression to CIN2+ outcome, given enrollment CIN1 histology and follow-up histology 
Enrollment Histology Histology Follow-Up Status at Follow-Up 
CIN1 
Normal/Negative Regress 
CIN1 Persist 
CIN2 Progress 
CIN2/3 Progress 
CIN3 Progress 
Cancer Progress 
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Table 3.2. 2 Progression to CIN2+ outcome given enrollment normal histology and follow-up histology 
Enrollment Histology Follow-Up Histology Status at Follow-Up 
Normal 
Normal/Negative Persist 
CIN1 
Non-Progress/ 
Persist* 
CIN2 Progress 
CIN2/3 Progress 
CIN3 Progress 
Cancer Progress 
*CIN2+ is main endpoint in analyses, as it warrants clinical intervention, e.g. (LEEP, etc.) [1] 
 
Table 3.2. 3 Progression to CIN2+ outcome for enrollment CIN1 histology utilizing follow-up cytology, 
given missing follow-up histology missing 
Enrollment Histology Cytology Follow-Up Status at Follow-Up 
CIN1 
Normal/Negative Regress 
LSIL Persist 
AGUS-L Persist 
ASCUS-L Persist 
HSIL Progress 
AGUS-H Progress 
ASCUS-H Progress 
ICC Progress 
 
Table 3.2. 4 Progression to CIN2+ outcome for enrollment normal histology utilizing follow-up cytology, 
given missing follow-up histology 
Enrollment Histology Follow-Up Cytology Status at Follow-Up 
Normal 
Normal/Negative Regress 
LSIL Non-Progress/Persist* 
AGUS-L Non-Progress/Persist* 
ASCUS-L Non-Progress/Persist* 
HSIL Progress 
AGUS-H Progress 
ASCUS-H Progress 
Cancer (AIS/SCC) Progress 
* CIN2+/HSIL+ is main endpoint in analyses, as it warrants immediate clinical intervention, e.g. 
(colposcopy/biopsy, etc.) [1] 
 
We defined progression as a cytology result of HSIL, LSIL-H, or ASC-H at follow-up; 
persistence as LSIL, ASCUS, or AGUS at follow-up; and regression as negative/normal cytology at 
follow-up (Table 3.2.3 and 3.2.4).  
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For women who received treatment (loop electrosurgical excision procedure, cold knife 
conization, hysterectomy, etc.) at a follow-up visit, the histological diagnosis from the treatment specimen 
will be used as their follow-up diagnosis. Women who were treated for CIN were excluded from further 
data analyses after their treatment. 
The outcome was dichotomized as the time to the first incidence or first progression of CIN from 
enrollment status. Person-time accumulated until progression to CIN2+ event, or at the last recorded 
follow-up visit. Administrative censoring occurred at 3 years’ post-study enrollment.  
Univariate distribution of the 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 
53, 54, 56, 58, 59, 66, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84) were examined individually, 
and categorized as HPV types by “high-risk,” “low-risk,” and “no HPV infection.” 
Correlates of CIN/cervical cancer examined as follows: 
• Age was examined as a continuous variable as well as a categorical variable 
• Race was categorized as a binary variable of either “Black” and “(Non-Hispanic) White” 
• Current cigarette smoking was categorized as  “Non-current smoker” vs. “Current smoker” 
• Parity was examined as a continuous variable and categorical variable 
• Current Oral contraceptive use was categorized as “Non-current Use” and “Current Use” 
• History of HPV Vaccination was categorized as “never received HPV vaccine” vs. “prior HPV 
vaccination” 
 Potential confounders were identified a priori and placed into an elastic net Cox regression model 
[51][52]. Effect measure modification was also assessed using the Akaike Information Criterion (AIC) to 
determine the quality of model fit for interactions between covariates of interest and HPV type risk group. 
 
Aim 2: To examine the association between aberrant methylation of imprinted genes and the regression 
(CIN1 to normal) of precancerous cervical lesions in the Cervical Intraepithelial Neoplasia Cohort Study 
(CINCS).  
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The exposure of aberrant methylation was treated as a continuous variable and transformed by the 
interquartile range (IQR) for CIN1 regression modeling. Median methylation scores of multiple CpG loci 
for each imprinted gene were also calculated.  
We also explored dichotomizing the outcome by establishing specific cutpoint for hyper- or 
hypo- methylation, given an expected value of 50% DNA methylation for monoallelically-expressed 
genes such as imprinted genes (as one allele is fully methylated while the other is completely 
unmethylated). Methylation levels deviating by 5% from this expected value were considered. Based on 
the data, methylation was coded continuously for the analyses. 
Regression of cervical lesions was defined as a diagnosis of negative/normal cytology at two 
consecutive follow-up visits (Table 3.3.1 and 3.3.2).  
 
Table 3.3. 1 CIN1 regression outcome, given enrollment CIN1 histology and follow-up histology  
Enrollment Histology Follow-Up Histology 
Outcome Status 
at Follow-Up 
CIN1 
Normal/Negative Regress 
CIN1 Persist 
CIN2 Progress 
CIN2/3 Progress 
CIN3 Progress 
Cancer Progress 
 
Table 3.3. 2 CIN1 regression outcome for enrollment CIN1 histology utilizing follow-up cytology, given 
missing histology 
Enrollment Histology Follow-Up Cytology Outcome Status at Follow-Up 
CIN1 
Normal/Negative Regress 
LSIL Persist 
AGUS-L Persist 
ASCUS-L Persist 
HSIL Progress 
AGUS-H Progress 
ASCUS-H Progress 
Cancer (AIS/SCC) Progress 
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Per conservative clinical practice, cytology results were utilized to determine regression status if the 
participants had missing histology data. Persistence was defined as a diagnosis of low-grade histology 
(CIN1) at follow-up or low-grade lesions during cytology testing (e.g. LSIL, ASC-US, AGUS-L). 
Progression was defined as a follow-up histological diagnosis of CIN2+, or as development of high-grade 
cytology, e.g. HSIL, LSIL-H, or ASC-H.  
Women with a negative/normal screening at one follow-up time point were not considered to 
have regressed for the main study analyses. For women who received treatment (LEEP, CKC, 
cryotherapy, or hysterectomy) at a follow-up visit, the histological diagnosis from the pre-treatment 
specimen was utilized. 
The covariates were examined as follows: 
• Age will be examined as a continuous variable as well as a categorical variable (categories to be 
explored) 
• HPV Status will be dichotomized as “HPV-Positive” and “HPV-Negative” 
• HrHPV Status will be dichotomized as “hrHPV-Positive” and “hrHPV-Negative (low-risk HPV 
or no HPV infection)” 
• Race was categorized as “Black”, “(Non-Hispanic) White”, and “Other” 
• History of Oral contraceptive use will be categorized as “Never Use” vs. “Ever Use” 
• Current cigarette smoking will be categorized as “Non-current smoker” vs. “Current smoker” 
• Parity will be examined as a continuous variable as well as a categorical variable. 
Associations between methylation at individual CpG loci and across the gene and time-to-CIN1 
regression were estimated using Cox regression models to produce HRs and 95% confidence intervals. 
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CHAPTER FOUR: HIGH-RISK HUMAN PAPILLOMAVIRUS GENOTYPES IN THE 
PROGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA 
Background 
Over 250,000 women in the United States (US) are living with  invasive cervical cancer (ICC), 
caused by oncogenic human papillomavirus HPV types [6, 53]. A total of 14 oncogenic or high-risk HPV 
(hrHPV) genotypes are causal factors for the development of ICC, which is preceded by high-grade 
cervical intraepithelial neoplasia (CIN2+)[54]. HPV genotypes 16 and 18 account for ~70% of cervical 
cancer cases, while hrHPV types 31, 33, 45, 52 and 58 account for approximately 15% of detected cases 
and 35, 59, 51, 56, 39, 68, 66 for the remaining 15% [7, 55, 56]. 
Cervical cancer is a highly preventable cancer by screening for cytology. In the US, annual 
cytology testing (Pap smear) has reduced morbidity and mortality from cervical cancer over the past 
several decades[57]. However, cytology testing alone has high specificity (93-98%), albeit relatively low 
sensitivity  (11-28%) for CIN2+ detection[1, 17].  
With the development of new screening technologies, the American Society of Colposcopy and 
Cervical Pathology (ASCCP) guidelines have evolved to improve detection of CIN2+ with the use of 
HPV testing [1]. Current ASCCP guidelines recommend liquid-based cytology (LBC) testing every 3-5 
years (vs. annually), with HPV co-testing to improve the sensitivity of cytology to detect CIN2+ among 
women ages 30 and older[58]. HPV-16/18 positive women with negative cytology are referred for 
immediate colposcopy. For negative cytology cases who test positive for hrHPV excluding types 16/18 
(“non-16/18 hrHPV-positive”), clinical management is less certain. Currently, follow-up 
recommendations for HPV-positive/cytology-negative cases include repeat testing after one year [1]. The 
increased number of follow-up visits results in increased burden of cost and psychological stress and 
decreased clinical visit adherence [1, 59, 60]. 
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To minimize over-screening, new methods of HPV-testing at screening have been developed to 
include additional genotyping. As risk of CIN2+ due to non-16/18 types is not well characterized [1, 61], 
new screening assays may help in establishing risk stratification categories by hrHPV genotype for 
women who are hrHPV-positive with negative cytology. Additionally, low-grade cytological 
abnormalities are currently referred for immediate colposcopy, with the exception of low-grade/HPV-
negative cases[1]. Risk stratification by non-16/18 hrHPV types may also possibly further triage women 
with low-grade cytology results, ultimately reducing the number and frequency of colposcopies in CIN 
management. 
With the advancement of new screening methods for cervical precancer, one must also consider 
the influence of HPV vaccination (bivalent, quadrivalent and 9-valent) on the distribution of HPV 
genotypes in the population. Any changes in prevalence due to immunity conferred from vaccination are 
important for contextualizing risk of CIN progression. 
 Improved risk management of patients who present with negative cytology, as well as low grade 
cervical abnormalities is essential to reducing the incidence of cervical cancer for all women. The use of 
hrHPV genotyping as a means of risk stratification would advance triaging methods for women who have 
low-grade cytology or are cytology-negative. This study aimed to investigate HPV genotypes in the 
development of cervical dysplasia. The objective of this study was to examine individual HPV types as 
predictors of progression to CIN2+ among negative and low-grade cytology patients in the Cervical 
Epithelial Neoplasia Cohort Study (CINCS). 
 
Methods 
Study population 
From June 2010 – April 2014, women attending 10 Duke University hospitals and clinics in 
Durham, North Carolina were invited to participate in CINCS, as previously described [62]. Briefly, all 
clinics used Duke-affiliated pathology laboratory for cytology and histological evaluation. CINCS 
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comprised of a cohort of 1303 women who were referred for a colposcopy following an abnormal LBC 
result from a pelvic exam. Participants were eligible if they provided written consent, were new visitors to 
the clinic, 18-79 years old, and were English or Spanish speakers. We excluded women who had received 
previous treatment for cervical lesions—cold knife conization (CKC), electrosurgical excision procedure 
(LEEP), cryotherapy, or hysterectomy; or had moved out of the study area or did not intend to receive 
follow-up care at one of the 10 Duke clinics. Women with no lesion or with a CIN1 diagnosis at 
enrollment who had at least one follow-up visit were included in the present analyses. Approval was 
granted by the Institutional Review Boards at Duke University (Durham, NC, USA), North Carolina State 
University (Raleigh, NC, USA) and University of North Carolina (Chapel Hill, NC, USA). 
 
Data collection and laboratory analyses 
At enrollment, participants had a physician-directed cervical examination with a colposcopy-
directed biopsy. Women diagnosed with normal/negative or CIN1 by colposcopic impression at 
enrollment were also included in the study, as prevalence of hrHPV was comparable to the hrHPV 
prevalence among those who underwent a biopsy and all women underwent colposcopy because of their 
initial abnormal cytology result. Study participants attended a clinical visit approximately every 6 months 
for the first two years, and at the end of 12 months for final third year, following clinical practice 
guidelines for management of CIN. During each follow-up visit, all women underwent a LBC test. Given 
an abnormal cytology result, clinic physicians performed a colposcopic examination and obtained a 
biopsy sample at follow-up visits if clinically necessary, according to physician’s best judgement and per 
clinical guidelines for management of precancerous cervical lesions [1]. Study staff administered a 
questionnaire at enrollment to ascertain information on any behavioral and clinical characteristics 
associated with CIN and cervical cancer, including age, race/ethnicity, current smoking status, history of 
HPV vaccination, current hormonal contraceptive use, and parity. 
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Ascertainment of Cervical Cytology and Histology 
To conduct a LBC test, the clinic physician utilized a spatula and cytobrush to obtain exfoliated 
cervical cells. Cervical specimens were suspended in a ThinPrep® vial containing proprietary fluid with at 
least 50% methanol (Cytyc®, Malborough, MA, USA) for cytological assessment. All study pathologists 
evaluated cytology according to Bethesda criteria [48]. The residual cervical exfoliated cell specimens 
were stored at 4°C prior to HPV DNA testing. 
Biopsy results were also reviewed and graded for severity by a pathologist at the study site. All 
histological biopsy specimens were tested for adequacy using the 2002 and 2012 ASCCP guidelines. 
Information on cytology and histology were abstracted from patient medical records.  
 
HPV Testing and Typology 
HPV typology was assessed using cervical exfoliated cells from the enrollment pelvic exam. 
ThinPrep® specimens were collected during the same enrollment visit and sent to Johns Hopkins 
University and the University of Hawaii Cancer Center for laboratory testing. Following DNA extraction, 
PGMY09/PGMY11 primers [49, 50] were used in PCR to target a 450-bp region of the HPV L1 genome. 
Amplification of the human β-globin gene was included as an internal control for sample sufficiency. 
HPV-positive specimens were subsequently genotyped by using the HPV Linear Array® (Roche 
Diagnostics, Branchburg, NJ, USA). This assay detects 37 HPV types— 6, 11, 16, 18, 26, 31, 33, 35, 39, 
40, 42, 45, 51, 52, 53, 54, 56, 58, 59, 66, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and 
CP6108. 
 
Statistical analyses 
HPV genotypes were evaluated individually and by high risk vs. low-risk status, where hrHPV 
types included 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 and lrHPV types included 6, 11, 
26, 40, 42, 53, 54, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 83, and 84. We also examined incidence and 
progression of CIN2+ in categories of hrHPV genotypes associated with risk of CIN3+ (defined by Stoler 
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et al.): A) 16/31/18 (>5% risk of CIN3+); B) 33/58/52/45 (2-5% risk of CIN3+); and C) 
39/68/35/51/59/56/66 (<2% risk of CIN3+) [63]. 
CIN progression was defined as a follow-up diagnosis of CIN2+ (CIN2, CIN2/3, CIN3, ICC) at a 
follow-up visit. Cytology results were utilized to determine progression status if the participants had 
missing histology data, per conservative clinical practice. A cytological diagnosis of high-grade squamous 
epithelial lesions (HSIL), LSIL-H (LSIL, cannot exclude HSIL) or ASC-H (ASC, cannot exclude HSIL) 
at follow-up was also considered a progression event. Persistence was defined as a diagnosis of low-grade 
histology (CIN1) at follow-up or low-grade lesions during cytology testing (e.g. low-grade squamous 
epithelial lesions or LSIL, atypical squamous cells of undetermined significance or ASC-US). Regression 
was defined as a follow-up diagnosis of negative/normal cytology or histology. For women who received 
treatment (LEEP, CKC, cryotherapy, or hysterectomy) at a follow-up visit, we utilized the histological 
diagnosis from the treatment specimen as their follow-up diagnosis.  
We conducted bivariable analyses to assess the distribution of HPV genotypes and other risk 
factors of cervical dysplasia and cervical cancer among women with no CIN lesion and CIN1 cases and 
by HPV vaccination history (Tables 4.1 and 4.2). We compared differences by enrollment CIN diagnosis 
within vaccination status using the Chi-Square test and Fisher’s Exact test for stratum with less than 10 
observations. The cumulative probabilities of progression to CIN2+ over 3 years were compared within 
HPV vaccination history (vaccinated vs. no vaccine) by enrollment diagnosis (no lesion vs. CIN1) using 
the Kaplan-Meier product-limit method and Log-rank test. Because probability estimates were similar 
regardless of enrollment diagnosis, subsequent analyses combined women with no lesion or CIN1 by their 
HPV vaccination status.  
Incidence rates and 95% confidence intervals were estimated for each HPV genotype, infection 
with any hrHPV/lrHPV type, and hrHPV risk categories among all infections and among single type 
infections (Tables 4.3 and 4.4). The Kaplan-Meier product-limit method was used to estimate the 
cumulative probability of progression to CIN2+ by hrHPV risk categories among single genotype 
infection (Figure 4.1). The Log-rank test was used to assess differences between progression probabilities 
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over time by infection status. In the time-to-event analyses, Cox proportional hazards regression models 
were utilized to estimate unadjusted and adjusted hazard ratios (HR) and 95% confidence intervals (95% 
CIs) for the association between HPV genotypes and progression to CIN2+ by vaccination status (Tables 
4.5 and 4.6). Time-to-progression was measured from the date of enrollment to the date of CIN2+ 
histological or HSIL+ cytological diagnosis, estimated in woman-months. Participants contributed 
woman-months up to the occurrence of progression or the date of the last attended clinical study visit. 
Participants who received treatment during the study were right censored from further follow-up analyses 
at the date of procedure. Administrative censoring occurred at 3 years.  
Confounders selected for the multivariable Cox regression model were determined a priori using 
conceptual models (directed acyclic graphs). Covariates considered for the analyses included continuous 
age at enrollment, HPV vaccination (yes vs. no), race/ethnicity (non-Hispanic White, Black/African-
American, Other), current smoking status at enrollment (current vs. non-current), current oral 
contraceptive use at enrollment (current vs. non-current), and parity (continuous). A penalized Cox 
proportional hazards regression model was employed to determine the strongest predictors of progression 
to CIN2+ from a large set of variables [64]. Model parameter optimization for progression to CIN2+ was 
determined using the c060 package for extended inference with elastic net Cox models, allowing for the 
inclusion of highly correlated variables [52, 65]. The optimal alpha-level selected by the algorithm was 
α=0.012. We assessed for modification using Akaike Information Criteria for model fit and found 
evidence of modification by race/ethnicity. Sensitivity analyses were conducted to assess for potential 
selection bias due to attrition. All statistical analyses were conducted using SAS version 9.4 (SAS 
Institute, Cary, NC) and R version 3.3.3 (Vienna, Austria). 
A total of 780 women of the 1303 enrolled CINCS participants had HPV DNA laboratory results. 
Of these, we excluded 36 women with an inconclusive CIN diagnosis, and 111 women with CIN2+ 
histological diagnosis. The remaining 631 women diagnosed with no lesion (n=389) or CIN1 (n=242) 
were considered for the analyses. 
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Results 
One quarter of CINCS participants with no lesion or CIN1 dropped out of the study after 
enrollment (N=159, 25.2%). There were no differences in characteristics between participants who 
dropped out after enrollment compared to those who remained in the longitudinal study (data not shown). 
Median age at enrollment among 472 women was 29.3 years (range: 19.7-64.7). One-fifth of CINCS 
participants had initiated HPV vaccination by their date of enrollment (22.9%, Table 4.1). Unvaccinated 
participants were 8 years older than those who were vaccinated (median age: 32.3 vs. 24.4 years), 
whereas two-thirds of vaccinated women were Non-Hispanic white relative to those with no prior 
vaccination (57.4% vs. 43.5%). Most women were non-current smokers regardless of vaccination history 
(81.5% unvaccinated, 86.1% vaccinated). A higher proportion of vaccinated women were current users of 
oral contraceptives compared to unvaccinated women (46.7% vs. 25.1%). 
Over 80% of CINCS participants had infection with any HPV type (88.6%) (Table 4.2). Most 
women tested positive for more than one genotype (53.6%). Approximately 65% of women had infection 
with any hrHPV type and 43% with any lrHPV type. The prevalence of any hrHPV type among 
unvaccinated women was slightly lower compared to women with HPV vaccination by enrollment 
(67.9% vs. 77.8%), however genotypes in the quadrivalent HPV vaccine (HPV-6, HPV-11, HPV-16, 
HPV-18) were less prevalent among vaccinated participants. Most participants were infected with 
multiple genotypes, regardless of vaccination status. The most frequently occurring hrHPV genotypes 
among single type infections were 16, 52, 35 in unvaccinated women, whereas genotypes 66, 51, and 16 
occurred most frequently for multiple infections. Vaccinated participants were predominately infected 
with other single non-16/18 hrHPV genotypes, including 51, 66, 52. The most prevalent hrHPV 
genotypes in multiple infections among women with a history of HPV vaccination included 66, 39, 51. 
No women in the study had infection with lrHPV types 11 and 64.  
Median study follow-up time was 22.4 months (range: 0.7-36 months). Only 11% (n=52 women) 
progressed to CIN2+ over 3 years of follow-up (n=20 with no lesion, n=32 with CIN1), compared to 418 
(89%) who did not progress (307 with no lesion, 110 with CIN1). Most CIN2+ events occurred among 
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unvaccinated participants (73%). Four of the 52 CIN2+ events occurred among patients who were HPV-
negative at enrollment, whereas the most frequently occurring types among those who progressed were 
HPV-16 (14 CIN2+ events) and HPV-51 (10 CIN2+ events). Only 3 of the 10 CIN2+ patients with HPV-
51 were co-infected with HPV-16/18. Median time-to-progression was 12.2 months (range: 0.8-36.0 
months). Unvaccinated women progressed to CIN2+ within a shorter duration compared to those with a 
history of HPV vaccine (9.1 months vs. 12.2 months).  
Over a 3-year period, the incidence rate of CIN2+ among unvaccinated HPV-positive 
unvaccinated women was 4.3 per the 1000 woman-months (95% CI, 2.4-6.9; Table 4.3), whereas the rate 
of CIN2+ among vaccinated women was 5.7 per 1000 woman-months (95% CI: 2.1-12.6). Unvaccinated 
women infected with hrHPV genotypes 16, 33, 51, and 35 (inclusive of both single and multiple 
infections) had the highest rates of CIN2+ over 3 years of follow-up. For vaccinated women, though the 
incidence rates of CIN2+ was highest among women infected with genotypes 33, 31, 45 and 16, there 
were less than 10 women exposed for each type. Among single infections, there were sparse data and 
events across vaccination status; however, rates of CIN2+ were highest among genotypes 66, 33, 51 
among unvaccinated women and 31, 39, and 16 among vaccinated women (Table 4.4). 
Unvaccinated participants infected with HPV-16 (single and multiple infection) experienced at least a 2-
fold higher risk of progression to CIN2+ compared to those not infected with HPV-16 (adjusted HR or 
aHR, 2.5; 95% CI, 1.2-5.6; Table 4.5). The risk of progression to CIN2+ was highest among unvaccinated 
women infected with HPV-16 (aHR, 2.5; 95% CI: 1.2-5.6), followed by HPV-51 (aHR, 2.2; 95% CI, 0.9-
4.9) and HPV-33 infection (aHR, 2.2; 95% CI: 0.5-9.3). High-risk genotypes HPV-16 and HPV-51 were 
most predictive progression to CIN2+ in CINCS women, with 3 times the risk of progression compared to 
women who did not have infection with either hrHPV type (HR: 3.2, 95% CI: 1.5-7.2). Using risk 
stratification groups developed by Stoler et al. [63], unvaccinated women infected with hrHPV types 16, 
31 or 18 (single and multiple infection) were twice as likely to progress to CIN2+ compared to women 
infected with other HPV types (HR: 2.1; 95% CI: 1.1-4.1; adjusted HR: 1.9; 95% CI: 1.0, 3.7; Table 4.6). 
For women with a single type infection and no history of the HPV vaccine, the 3-year cumulative 
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probability of progression to CIN2+ was highest for infection with genotypes 16/31/18, followed by those 
infected with types 33/58/52/45 (Figure 4.1). 
Discussion 
This 3-year prospective study investigated progression to CIN2+ by HPV genotype among 
women in North Carolina with no CIN lesion and colposcopy-confirmed CIN1 at enrollment. The most 
prevalent hrHPV types among unvaccinated women were 66, 51, 16 in multiple infections and types 16, 
52, 35 in single infections. The highest CIN2+ incidence rates among unvaccinated CINCS participants 
generally corresponded with prevalence estimates for any infection type, with the exception of high 
incidence in hrHPV-33 infection. However, incidence rates among single infections were highest among 
types 66, 33 and 51. In women with a history of HPV vaccination, there was decreased the prevalence of 
types 6, 11, 16, and 18, as expected. HrHPV types with the highest CIN2+ incidence rates (31, 39, 16 in 
single infections; 33, 31, and 45 in multiple infection) were not the most prevalent types (51, 66, 52/58 in 
single infections; 66, 39, 51 in multiple infections). HPV-16 and HPV-51 collectively were most 
predictive of progression to CIN2+ among unvaccinated participants, whereas hrHPV types 33 and 42 
were most predictive in vaccinated women. These findings increase the understanding of HPV 
epidemiology and attribution of HPV genotypes in high-grade CIN progression, implicating potentially 
new screening criteria for clinical screening and management guidelines. 
We assessed the predictability of hrHPV types for progression to CIN2+ individually and in three 
risk categories. Previous data suggest that collective assaying of hrHPV types could increase specificity 
of HPV testing while maintaining high sensitivity (>90%) to detect CIN2+ [66]. The present study 
findings, when stratified by absolute risk of CIN2/3+ [63] support that types 16, 31 and 18 may 
distinguish women at highest risk of progression to CIN2+ in the CINCS population. Results from the BD 
Onclarity™ HPV Clinical trial proposed stratification of patients according to CIN2/3+ risk attributed to 
HPV genotype [63]. In the BD trial, baseline absolute risk of CIN2+ was 30.1%, 17.6% and 12.3%, 
respectively, for hrHPV types 16, 31 and 18. The risk of CIN3+ was 20.0%, 9.9%, 6.6%, respectively for 
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16, 31, 18. Though the absolute risk of CIN2/3+ attributed to HPV-51 was 1.6%-9.0% in the BD 
Onclarity™ HPV Clinical Trial, our study may suggest that HPV-51, as well as established oncogenic 
genotype 16, are potentially predictive of progression to CIN2+ over a 3-year period. 
Cross-sectional studies of HPV prevalence have attributed genotypes 16, 18 and 45 to 
CIN2+/ICC [61, 67]. By contrast, a US-based screening population study showed that 16, 31, and 18 may 
indicate the highest risk of CIN2+ (20%, 10%, 6.6%, respectively) compared to other hrHPV types [68]. 
Our study, though a smaller sample size, provides useful information regarding the risk of progression to 
CIN2+ over time among negative and low-grade cases relative to case-control or prevalence study design. 
The current clinical guidelines for HPV co-testing with LBC recommend genotyping for hrHPV, and 
specifically for HPV 16/18, given a negative cytology result [1].  However, the predictive use of other 
hrHPV types in progression has not been well characterized for CIN management. It is imperative in the 
case of negative cytology, ASCUS and potentially LSIL results that the risk of CIN2/3+ be adequately 
quantified to avoid excessive follow-up and to continue improving efficacy of overall precancer 
screening. 
As new methods for screening are developed, one must also consider the impact of single and 
multiple type HPV infections in risk assessment for ICC. Previous research suggests there may be a 
clustering of homologous HPV types during HPV infection [69]. Infection with lrHPV types has been 
shown to decrease the potential for progression to more severe cervical lesions [70]. Infection with both 
lrHPV and hrHPV types may prolong the diagnosis of cancer in situ or squamous cervical cancer 
compared to cases infected with only hrHPV types [71]. Data on the risk of progression to CIN2+ due to 
any single HPV type infection in the CINCS cohort were inconclusive due to small sample size, thus the 
presence of multiple type infections should be factored into the interpretations of the results. However, as 
most CIN2+ events with HPV-51 infection were not co-infected with hrHPV genotypes 16 or 18, the rate 
of progression to CIN2+ for women with multiple infection with types inclusive of genotype 51 is 
noteworthy for future investigation in larger cohorts.  
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The potential for genotypic interactions in multiple HPV infections may be addressed with the 
introduction of the recently FDA approved 9-valent (9v) vaccine, which protects against genotypes 
6,11,16,18, 31, 33, 35, 52 and 58 [72]. Clinical trial data on the quadrivalent vaccine demonstrated cross-
protective efficacy against CIN2+ associated with types 33, 31, 45, and 51 [73]. Though we did not 
observe high prevalence or attribution of progression to CIN2+ for all types included in the 9v vaccine in 
the CINCS cohort regardless of vaccination status, the inclusion of other hrHPV types in the latest 
iteration of the vaccine may show increased protection against infection with multiple and related 
genotypes and ultimately reduce CIN2+ risk.  
To our knowledge, this study is among the few to prospectively examine progression to CIN2+ 
by HPV genotype who had normal epithelia or CIN1 following an abnormal cytology test. The use of 
longitudinal data to explore genotype-specific CIN2+ risk is advantageous compared to cross-sectional 
studies to quantify risk over time. The data on predictive HPV types were strengthened by the use of the 
elastic net Cox regression model for high-dimensional variable selection. In order to determine which 
combination of the genotypes may be most predictive of progression to CIN2+, the elastic net method 
allowed for the inclusion of correlated variables, as would be the case with HPV genotypes that are 
phylogenically-related.  
Among potential limitations, we did not assess HPV infection by genotype at study follow-up, 
which would have improved the ability to examine persistent HPV infection and observe any genotypic 
changes in infection in relation to progression to CIN2+. Future work would be strengthened with 
multiple HPV genotype measurements throughout the study period. There was potential for selection bias 
due to attrition, but no differences were observed between women who dropped out compared to women 
who remained in the study. It is also possible that there was an over-estimation of person-time contributed 
by each patient, as the person-time was dependent on study visit adherence and clinical recommendations 
for CIN follow-up. Small sample size impacted the ability to make strong inferences on CIN2+ risk 
attributed to a single HPV genotype, as well as among vaccinated CINCS participants, which comprised 
only 20% of the total analytic sample. There were fewer CIN2+ events and fewer women infected with 
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certain HPV genotypes in the vaccinated group, affecting the precision of HR estimates. However, it 
should be noted that fewer events among women with a history of HPV vaccination potentially 
demonstrates the efficacy of protection against development of CIN2+. The endpoint was defined as 
CIN2+, given the short duration of follow-up for the study. Observing CIN3+ events over a longer study 
duration would have strengthened our analyses, as a smaller proportion of CIN2+ cases progress to 
invasive cancer compared to CIN3+ cases [74]. Though the CIN3+ endpoint is more proximal to invasive 
cancer, there is clinical value in determining risk stratification earlier in the natural history of HPV-
associated CIN. 
 In conclusion, the data support the need to further investigate the utility of non-16/18 hrHPV 
types for predicting progression to CIN2+ among women with negative or low-grade cytology/histology 
over time. Preventive strategies for CIN will benefit from increased knowledge of individual and 
composite risk attribution of HPV genotypes to CIN progression. With the increasing vaccine coverage in 
the population and subsequent shifts in HPV prevalence, it is important to identify hrHPV types that may 
require more immediate intervention and that can improve the risk stratification model for the clinical 
management of CIN. Successful characterization and implementation of hrHPV type-specific risk 
stratification would shift the screening paradigm, creating a new template for clinical management 
practice of CIN and cervical cancer prevention in the US. 
 
  
3
2
 
 
Tables and Figures 
Table 4. 1 Enrollment characteristics of 472 CINCS* colposcopy participants with normal histology or low-grade CIN (CIN1)*, stratified by 
HPV† vaccination status 
Enrollment 
characteristic 
No prior HPV† Vaccination(n=364) 
N (%) 
Prior HPV† Vaccination (n=108) 
N (%) 
N (%) 
Normal 
N (%) 
CIN1* 
N (%) p-value|| N (%) 
Normal 
N (%) 
CIN1* 
N (%) p-value|| 
Total 364 (77.1) 218 (59.9) 146 (40.1)  108 (22.9) 55 (50.9) 53 (49.1)  
Age (years)         
Median 
(Range) 
29.8  
(20.1-64.7) 
32.3 
(20.5-64.7) 
28.5 
(20.1-64.4) 0.19 
24.5 
(19.7-39.9) 
24.4 
(20.9-35.2) 
24.5 
(19.7-39.9) 0.30 
18-24 84 (23.1) 32 (14.7) 52 (35.6)  61 (56.5) 31 (56.4) 30 (56.6)  
25-29 102 (28.0) 60 (27.5) 42 (28.8)  39 (36.1) 21 (38.2) 18 (34.0)  
30-34 52 (14.3) 39 (17.9) 13 (8.9)  6 (5.6) 2 (3.6) 4 (7.5)  
35+ 126 (34.6) 87 (39.9) 39 (26.7)  2 (1.8) 1 (1.8) 1 (1.9)  
Race    0.39    0.80 
Non-Hispanic White 158 (43.5) 98 (45.2) 60 (41.1)  62 (57.4) 34 (61.8) 28 (52.8)  
Black 166 (45.7) 101 (46.5) 65 (44.5)  31 (28.7) 14 (25.5) 17 (32.1)  
Other§ 39 (10.8) 18 (8.3) 21 (14.4)  15 (13.9) 7 (12.7) 8 (15.1)  
Current Smoker‡    0.78    1.0 
No 296 (81.5) 173 (79.7) 123 (84.3)  93 (86.1) 46 (83.6) 47 (88.7)  
Yes 67 (18.5) 44 (20.8) 23 (15.7)  15 (13.9) 9 (16.4) 6 (11.3)  
Current Oral 
Contraceptive Use‡    0.10    0.15 
No 248 (74.9) 144 (75.8) 104 (73.8)  56 (53.3) 29 (52.7) 27 (54.0)  
Yes 83 (25.1) 46 (24.2) 37 (26.2)  49 (46.7) 26 (47.3) 23 (46.0)  
Parity‡    0.25    0.16 
Nulliparous 155 (44.2) 90 (43.1) 65 (45.8)  85 (79.4) 47 (85.5) 38 (73.1)  
Primiparous (1) 96 (27.4) 61 (29.2) 35 (24.7)  16 (15.0) 5 (9.1) 11 (21.2)  
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Multiparous (2+) 100 (28.5) 58 (27.8) 42 (29.6)  6 (5.6) 3 (5.5) 3 (5.8)  
High-risk HPV†    0.13    0.11 
Negative 117 (32.1) 82 (37.6) 35 (24.0)  24 (22.2) 16 (29.1) 8 (15.1)  
Positive 247 (67.9) 136 (62.4) 111 (76.0)  84 (77.8) 39 (70.9) 45 (84.9)  
* CIN = cervical intraepithelial neoplasia; CINCS = Cervical Intraepithelial Neoplasia Cohort Study 
† HPV = Human papillomavirus 
‡ Numbers do not add up to the total sample size due to missing data 
§ “Other” includes Hispanic/Asian/Pacific Islander/Native American/Multiracial 
|| Chi-Square test p-value, comparing normal histology to low-grade CIN by vaccination status. Fisher’s Exact test p-value used for strata where 
n<10.  
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Table 4. 2 Distribution of single/multiple HPV* genotypes in 472 CINCS† participants with normal histology/CIN1† at enrollment, stratified by 
HPV* vaccination status 
HPV* Genotype 
No Prior HPV* Vaccination (n=364) Prior HPV Vaccination* (n=108) 
HPV*-Positive 
N (%) 
Single 
N (%) 
Multiple 
N (%) 
HPV*-Positive 
N (%) 
Single 
N (%) 
Multiple 
n (%) 
Total Infected 
n (%) 317 (87.1) 152 (41.8) 165 (45.3) 101 (93.5) 42 (38.9) 59 (54.6) 
High-Risk       
All types 247 (67.9) 109 (71.7) 138 (83.6) 84 (77.8) 34 (80.9) 50 (84.8) 
16 40 (11.0) ‡ 16 (10.5) ‡ 24 (14.6) ‡ 10 (9.3) 3 (7.1) 7 (11.9) 
18 22 (6.0) 0 (0.0) 6 (4.0) 1 (0.9) 0 (0.0) 1 (1.7) 
31 22 (6.0) 8 (5.3) 14 (8.5) 2 (1.9) 1 (2.4) 1 (1.7) 
33 7 (1.9) 1 (0.7) 6 (3.6) 2 (1.9) 0 (0.0) 2 (3.4) 
35 20 (5.5) 11 (7.2) ‡ 9 (5.5) 4 (3.7) 1 (2.4) 3 (5.1) 
39 29 (8.0) 7 (4.6) 22 (13.3)  12 (11.1) ‡ 2 (4.8) 10 (17.0) ‡ 
45 15 (4.1) 7 (4.6) 8 (4.9) 2 (1.9) 0 (0.0) 2 (3.4) 
51 36 (9.9) ‡ 8 (5.3) 28 (17.0) ‡ 20 (18.5) ‡ 11 (26.2) ‡ 9 (15.3) ‡ 
52 33 (9.1 15 (9.9) ‡ 18 (10.9) 10 (9.3) 4 (9.5) ‡ 6 (10.2) 
56 20 (5.5) 4 (2.6) 16 (9.7) 7 (6.5) 0 (0.0) 7 (11.9) 
58 19 (5.0) 6 (4.0) 12 (7.3) 7 (6.5) 4 (9.5) ‡ 6 (10.2) 
59 26 (7.1) 7 (4.6) 19 (11.5) 9 (8.3) 1 (2.4) 8 (13.6) 
66 46 (12.6) ‡ 9 (5.9) 37 (22.4) ‡ 20 (18.5) ‡ 6 (14.3) ‡ 14 (23.7) ‡ 
68 16 (4.4) 4 (2.6) 12 (7.3) 4 (3.7) 1 (2.4) 3 (5.1) 
Low-Risk       
All types 169 (46.4) 40 (26.3) 129 (78.2) 54 (50.0) 8 (19.1) 46 (78.0) 
6 13 (3.6) 5 (1.4) 8 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 
11 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
26 3 (0.8) 1 (0.7) 2 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 
40 8 (2.2) 1 (0.7) 7 (4.2) 2 (0.4) 0 (0.0) 2 (3.4) 
42 13 (3.6) 1 (0.7) 12 (7.3) 3 (2.8) 0 (0.0) 3 (5.1) 
53 35 (9.6)  14 (9.2) ‡ 21 (12.7) 17 (15.7) 3 (7.1) 14 (23.7) 
54 12 (3.3) 2 (1.3) 10 (6.1) 4 (3.7) 0 (0.0) 4 (6.8) 
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55 13 (3.6) 2 (1.3) 11 (6.7) 1 (0.9) 0 (0.0) 1 (1.7) 
61 22 (6.0) 3 (2.0) 19 (11.5) 5 (4.6) 0 (0.0) 5 (8.5) 
62 29 (8.0) 2 (1.3) 27 (16.4) 13 (12.0) 3 (7.1) 10 (17.0) 
64 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
67 6 (1.7) 1 (0.7) 5 (3.0) 2 (1.9) 1 (2.4) 1 (1.7) 
69 1 (0.3) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 
70 16 (4.4) 5 (3.3) 11 (6.7) 4 (3.7) 0 (0.0) 4 (6.8) 
71 2 (0.6) 0 (0.0) 2 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 
72 4 (1.1) 0 (0.0) 4 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 
73 12 (3.3) 1 (0.7) 1 (6.7) 3 (2.8) 0 (0.0) 3 (5.1) 
81 18 (5.0) 0 (0.0) 18 (10.9) 2 (1.9) 0 (0.0) 2 (3.4) 
82 8 (2.2) 1 (0.7) 7 (4.2) 1 (0.9) 0 (0.0) 1 (1.7) 
83 7 (1.9) 1 (0.7) 6 (3.6) 7 (6.5) 0 (0.0) 7 (11.9) 
84 23 (6.3) 0 (0.0) 23 (13.9) 5 (4.6) 1 (2.4) 4 (6.8) 
* HPV = Human papillomavirus 
† CINCS = Cervical Intraepithelial Neoplasia Cohort Study; CIN = cervical intraepithelial neoplasia 
‡ Top 3 most prevalent high-risk HPV genotypes in the among infection type stratum (all vs. single vs. multiple)
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Table 4. 3 Incidence rates of CIN2+*, stratified by HPV† genotype‡ infection and vaccination history among 472 CINCS* participants over 3 years 
of follow-up 
 No HPV† Vaccination (n=364) HPV† Vaccination (n=108) 
HPV† Genotype 
CIN2+* 
Events 
Woman-
Months§ 
Incidence Rate 
(95% CI)|| 
CIN2+* 
Events 
Woman-
Months|| 
Incidence Rate 
(95% CI)|| 
Total 34 7860 4.3 (3.0, 6.0) 14 2230 6.3 (3.6, 10.3) 
High-Risk       
All 30 5428 5.5 (3.8, 7.8) 13 1729 7.5 (4.2, 12.5) 
 16/31/18¶ 14 1684 8.3 (4.7, 13.6) 4 201 2.0 (0.6, 4.8) 
33/58/52/45¶ 6 1597 3.8 (1.5, 7.8) 5 482 1.0 (0.4, 2.3) 
39/68/35/51/59/56/66¶ 10 3255 3.1 (1.6, 5.5) 4 1248 3.2 (1.0, 7.7) 
16 10 891 11.2 (5.7, 20.0) 3 175 17.1 (4.4, 46.7)¶ 
18 2 535 3.7 (0.6, 12.4)¶ 0 20 0.0 (0.0) 
31 2 407 4.9 (0.8, 16.2) 1 26 38.5 (1.9, 189.7)¶ 
33 2 182 11.0 (1.8, 36.3)¶ 1 18 55.6 (27.8, 274.0)¶ 
35 3 371 8.1 (2.1, 22.0)¶ 1 64 15.6 (0.7, 77.1)¶ 
39 4 592 6.8 (2.1, 16.3) 2 267 7.5 (1.3, 24.8) 
45 1 361 2.8 (0.1, 13.7)¶ 1 41 24.4 (1.2, 120.3)¶ 
51 7 718 9.7 (4.3, 19.3) 2 342 5.8 (1.0, 19.3)¶ 
52 5 669 7.5 (2.7, 16.6) 1 218 4.6 (0.2, 22.6)¶ 
56 2 491 4,1 (0.7, 13.5) 2 186 10.8 (1.8, 35.5)¶ 
58 2 385 5.2 (0.9, 17.2) 3 222 13.5 (3.4, 36.8)¶ 
59 3 637 4.7 (1.2, 12.8) 0 154 0.0 (0.0) 
66 4 954 4.2 (1.3, 10.1) 2 439 4.6 (0.8, 15.1) 
68 1 376 2.7 (0.1, 13.1) 0 97 0.0 (0.0) 
Low-Risk       
All 17 3732 4.6 (2.7, 7.1) 6 1130 5.3 (2.2, 11.0) 
6 2 275 7.3 (1.2, 24.0)¶ 0 -- 0.0 (0.0) 
11 -- -- -- -- -- -- 
26 1 71 14.1 (0.7, 69.5)¶ -- -- -- 
40 0 154 0.0 (0.0) 0 53 0.0 (0.0) 
42 2 313 6.4 (1.1, 21.1) 3 75 40.0 (10.1, 108.9)¶ 
53 4 824 4.9 (1.5, 11.7) 3 294 10.2 (2.6, 27.8) 
54 0 237 0.0 (0.0) 1 74 13.5 (0.7, 66.7)¶ 
55 3 267 11.2 (2.9, 30.6) 0 36 0.0 (0.0) 
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61 5 589 8.5 (3.1, 18.8) 1 74 13.5 (0.7, 66.7)¶ 
62 2 607 3.3 (0.6, 10.9) 0 221 0.0 (0.0) 
64 -- -- -- -- -- -- 
67 1 149 6.7 (0.3, 33.1)¶ 0 53 0.0 (0.0) 
69 0 24 0.0 (0.0) -- -- -- 
70 1 434 2.3 (0.1, 11.4) 0 92 0.0 (0.0)) 
71 0 72 0.0 (0.0) -- -- -- 
72 0 83 0.0 (0.0) -- -- -- 
73 1 217 4.6 (0.2, 22.7) 1 48 20.8 (1.0, 102.7)¶ 
81 0 475 0.0 (0.0) 0 56 0.0 (0.0) 
82 1 231 4.3 (0.2, 21.4)¶ 0 11 0.0 (0.0) 
83 1 170 5.9 (0.3, 29.0)¶ 2 154 13.0 (2.1, 42.9)¶ 
84 3 552 5.4 (1.4, 14.8) 0 135 0.0 (0.0) 
* CINCS = Cervical Intraepithelial Neoplasia Cohort Study; CIN = cervical intraepithelial neoplasia 
† HPV = Human papillomavirus 
‡ Includes single and multiple genotype infections 
§ Sum of woman-months for all women infected with noted genotype at enrollment at risk of developing CIN2+ 
|| IR = Incidence rate per 100 woman-months; 95% CI = 95% Confidence interval  
¶ N<10 women “exposed” or infected with HPV type 
** Risk stratification groups adapted from Stoler et al. 2017 [63]
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Table 4. 4 Incidence rates of CIN2+* by single HPV† infection, stratified by vaccination status among 472 CINCS* participants over 3 
years of follow-up 
 No HPV† Vaccination (n=152) HPV† Vaccination (n=42) 
HPV† Genotype 
CIN2+* 
Events 
Woman-
Months 
Incidence Rate 
(95% CI)‡ 
CIN2+* 
Events 
Woman-
Months 
Incidence Rate 
(95% CI) ‡ 
Total 14 3323 4.2 (2.4, 6.9) 5 877 5.7 (2.1, 12.6) 
High-Risk       
 16/31/18||  2 678 3.0 (0.5, 9.7) 2 73 27.4 (4.6, 90.5)¶ 
33/58/52/45||  3 736 4.1 (1.0, 11.1) 2 216 9.3 (1.6, 30.6)¶ 
39/68/35/51/59/56/66||  5 1055 4.7 (1.7, 10.5)¶  1 422 2.4 (0.1, 11.7) 
16 2 393 5.1 (0.9, 16.8) 1 67 14.9 (0.7, 73.6) § 
18 0 148 0.0 (0.0) -- -- -- 
31 0 137 0.0 (0.0) 1 6 166 (8.0, 822.0) § 
33 1 30 33.3 (1.7, 164.4) § -- -- -- 
35 2 197 10.1 (1.7, 33.5) 0 9 0.0 (0.0) 
39 0 128 0.0 (0.0) 1 24 41.7 (2.1, 205.5) § 
45 0 208 0.0 (0.0) -- -- -- 
51 2 144 13.9 (2.3, 45.9) § 0 226 0.0 (0.0) 
52 1 369 2.7 (0.1, 13.4) 1 109 9.2 (0.5, 45.3) § 
56 0 100 0.0 (0.0) -- -- -- 
58 1 129 7.8 (0.4, 38.2) § 1 107 9.3 (0.5, 46.1) § 
59 0 181 0.0 (0.0) 0 32 0.0 (0.0) 
66 1 162 61.7 (3.1, 304.4) § 0 112 0.0 (0.0) 
68 0 144 0.0 (0.0) 0 19 0.0 (0.0) 
Low-Risk       
All 4 791 5.1 (1.6, 12.2) 0 165 0.0 (0.0) 
6 1 71 14.1 (0.7, 69.5) § -- -- -- 
11 -- -- -- -- -- -- 
26 0 36 0.0 (0.0) -- -- -- 
40 0 12 0.0 (0.0) -- -- -- 
42 0 12 0.0 (0.0) -- -- -- 
53 1 284 3.5 (0.2, 17.4) 0 64 0.0 (0.0) 
54 0 24 0.0 (0.0) -- -- -- 
55 0 48 0.0 (0.0) -- -- -- 
61 1 57 17.5 (0.8, 86.5) § -- -- -- 
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62 1 16 62.5 (3.1, 308.2)§ 0 59 0.0 (0.0) 
64 -- -- -- -- -- -- 
67 0 36 0.0 (0.0) 0 17 0.0 (0.0) 
69 -- -- -- -- -- -- 
70 0 120 0.0 (0.0) -- -- -- 
71 -- -- -- -- -- -- 
72 -- -- -- -- -- -- 
73 0 6 0.0 (0.0) -- -- -- 
81 -- -- -- -- -- -- 
82 0 36 0.0 (0.0) -- -- -- 
83 0 34 0.0 (0.0) -- -- -- 
84 -- -- -- 0 25 0.0 (0.0) 
* CINCS = Cervical Intraepithelial Neoplasia Cohort Study; CIN = cervical intraepithelial neoplasia 
† HPV = Human papillomavirus 
‡ IR = Incidence rate per 100 woman-months; 95% CI = 95% Confidence interval 
§ N<10 women “exposed” or infected with HPV type 
|| Risk stratification groups adapted from Stoler et al. 2017 [63] 
¶ p<0.05  
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Table 4. 5 Risk of progression to CIN2+*, stratified by HPV† genotypes‡ among 472 CINCS* participants by HPV† vaccination history 
HPV† 
Genotype 
No HPV† Vaccination (n=364) HPV† Vaccination (n=108) 
Unadjusted HR 
(95% CI)§ 
Adjusted HR 
(95% CI)§ 
Predictive 
Model HR 
(95% CI)§|| 
Unadjusted HR 
(95% CI)§ 
Adjusted HR 
(95% CI)§ 
Predictive 
Model HR 
(95% CI)§||  
High-Risk       
All 1.7 (0.8, 3.6) 1.6 (0.7, 3.6) -- 4.1 (0.5, 31.6) 5.7 (0.7, 46.3) -- 
16 2.7 (1.3, 5.6)**  2.5 (1.2, 5.6)**  3.2 (1.5, 7.2)**  4.3 (1.1, 15.8)¶ 10.0 (2.0, 50.0)¶ -- 
18 0.7 (0.2, 3.1) 0.7 (0.2, 2.9) -- -- -- -- 
31 1.0 (0.2, 4.3) 1.2 (0.3, 5.1) -- 9.9 (1.2, 79.5)¶ 18.4 (1.9, 180.0)¶ -- 
33 2.2 (0.5, 9.3) 2.4 (0.5, 10.8) -- 8.5 (1.1, 66.6)¶ 6.5 (0.5, 93.1) 11.1 (1.4, 88.8)¶ 
35 1.8 (0.6, 5.9) 1.6 (0.5, 5.7) -- 3.7 (0.5, 29.0) 6.3 (0.7, 55.0) -- 
39 1.5 (0.5, 4.2) 1.9 (0.6, 5.7) -- 1.3 (0.3, 6.0) 1.6 (0.3, 7.6) -- 
45 0.6 (0.1, 4.2) 0.7 (0.1, 5.3) -- 4.3 (0.6, 33.1) 7.6 (0.8, 71.4) -- 
51 2.2 (1.0, 4.9) 2.1 (0.9, 4.9) 3.2 (1.3, 7.6)**  1.0 (0.2, 4.7) 1.1 (0.2, 5.1) -- 
52 1.6 (0.6, 4.1) 1.8 (0.7, 4.6) -- 0.7 (0.1, 5.0) 0.5 (0.1, 4.1) -- 
56 0.9 (0.2, 3.6) 0.9 (0.2, 3.7) -- 2.0 (0.4, 8.9) 3.5 (0.7, 18.7) -- 
58 1.0 (0.2, 4.3) 0.9 (0.2, 3.9) -- 2.3 (0.6, 8.3) 2.4 (0.6, 10.4) -- 
59 1.0 (0.3, 3.4) 1.0 (0.3, 3.4) -- -- -- -- 
66 0.9 (0.3, 2.4) 1.0 (0.4, 2.9) -- 0.6 (0.1, 2.9) 0.6 (0.1, 3.0) -- 
68 0.6 (0.1, 4.2) 0.6 (0.1, 4.2) -- -- -- -- 
Low-Risk      -- 
All 0.9 (0.5, 1.7) 0.8 (0.4, 1.6) -- 0.8 (0.3, 2.4) 0.9 (0.3, 2.7) -- 
6 1.6 (0.4, 6.6) 1.5 (0.4, 6.5) -- -- -- -- 
11 -- -- -- -- -- -- 
26 2.9 (0.4, 21.4) 3.4 (0.4, 26.3) -- -- -- -- 
40 -- -- -- -- -- -- 
42 1.3 (0.3, 5.4) 1.7 (0.4, 7.2) -- 7.8 (2.1, 29.2)¶ 23.8 (1.6, 360.9)¶ 8.3 (2.2, 31.8)¶ 
53 1.0 (0.4, 2.9) 1.0 (0.3, 2.7) -- 1.9 (0.5, 6.8) 3.3 (0.8, 13.5) -- 
54 -- -- -- 3.2 (0.4, 24.6) 4.6 (0.5, 40.5) -- 
55 2.6 (0.8, 8.6) 2.3 (0.7, 7.6) -- -- -- -- 
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* CIN = cervical intraepithelial neoplasia; CINCS= Cervical Intraepithelial Neoplasia Cohort Study 
† HPV = human papillomavirus  
‡ Includes single and multiple genotype infections 
§ HR = hazard ratio; 95% CI = 95% confidence interval; adjusted HR controls for continuous age, race, current smoking status, history of HPV 
vaccine, continuous parity, and current oral contraceptive use 
|| Predictive elastic net Cox regression model. Model parameter specifications: α=0.012, λ = 1.7. Adjusted for other variables in model. 
¶ p<0.05 
** p<0.001  
61 1.9 (0.7, 4.9) 2.2 (0.8, 5.8) -- 2.9 (0.4, 22.3) 4.2 (0.4, 44.6) -- 
62 0.7 (0.2, 2.7) 0.7 (0.2, 2.8) -- -- -- -- 
64 -- -- -- -- -- -- 
67 1.3 (0.2, 9.3) 1.2 (0.2, 9.3) -- -- -- -- 
69 -- -- -- -- -- -- 
70 0.5 (0.1, 3.4) 0.4 (0.1, 3.2) -- -- -- -- 
71 -- -- -- -- -- -- 
72 -- -- -- -- -- -- 
73 1.01 (0.1, 7.4) 1.3 (0.2, 10.0) -- 4.6 (0.6, 35.3) 6.4 (0.7, 55.5) -- 
81 -- -- -- -- -- -- 
82 0.8 (0.1, 6.0) 0.7 (0.1, 5.4) -- -- -- -- 
83 0.7 (0.1, 5.4) 1.4 (0.2, 10.6) -- 2.5 (0.5, 11.1) 1.0 (0.2, 5.7) -- 
84 1.0 (0.3, 3.4) 0.7 (0.2, 2.9) -- -- -- -- 
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Table 4. 6 Risk of progression to CIN2+*, stratified by risk groups for high-risk HPV† infection‡ 
HPV† Genotype 
No HPV† Vaccination (n=364) HPV† Vaccination (n=108) 
Unadjusted HR 
(95% CI)§ 
Adjusted HR 
(95% CI)§ 
Unadjusted HR 
(95% CI)§ 
Adjusted HR 
(95% CI)§ 
16/31/18||  2.1 (1.1, 4.1)** 1.9 (1.0, 3.7) 5.7 (1.7, 18.9)¶ 17.2 (3.4, 87.6)¶ 
33/58/52/45||  1.4 (0.7, 2.8) 1.5 (0.7, 3.1) 1.9 (0.6, 5.6) 1.8 (0.5, 6.2) 
39/68/35/51/59/56/66||  1.5 (0.8, 2.8) 1.6 (0.8, 3.1) 0.9 (0.3, 2.6) 1.1 (0.4, 3.4) 
* CIN = cervical intraepithelial neoplasia; CINCS= Cervical Intraepithelial Neoplasia Cohort Study 
† HPV = human papillomavirus 
‡ Includes single and multiple infections 
§ HR = hazard ratio; 95% CI = 95% confidence interval; adjusted HR controls for continuous age, race, current smoking status, history of HPV 
vaccine, continuous parity, and current oral contraceptive use 
|| Risk stratification groups adapted from Stoler et al. 2017 [63] 
¶ p<0.05 
** p<0.001  
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Figure 4. 1 3-year cumulative probability of CIN2+* progression in 194 unvaccinated and vaccinated CINCS women with single HPV† type 
infection, stratified by risk group 
 
* CIN = Cervical intraepithelial neoplasia 
† HPV = Human papillomavirus 
‡ Risk stratification groups adapted from Stoler et al. 2017 [63] 
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CHAPTER FIVE: DNA METHYLATION OF IMPRINTED GENE CONTROL REGIONS 
IN THE REGRESSION OF LOW-GRADE CERVICAL LESIONS 
Background 
As of 2014, an estimated 250,000 women were living with cancer of the cervix in the United 
States (US) [53]. At current incidence and mortality rates, approximately 13,000 women will be 
diagnosed with cervical cancer in the US in 2017, resulting in over 4,000 subsequent deaths [75]. Though 
overall rates of cervical cancer in the US have decreased over time, the highest rates of cervical cancer 
incidence and mortality occur in the Southern states [75]. 
Nearly all invasive cervical cancers are caused by the human papillomavirus (HPV), a sexually 
transmitted infection that affects over 79 million people in the US [2, 6, 76]. While most HPV infections 
clear spontaneously, oncogenic or high-risk HPV (hrHPV) types often lead to persistent HPV infection 
and subsequent high-grade cervical intraepithelial neoplasia (CIN2+), a risk factor for progression to 
invasive cervical cancer [54].  
Current cervical cancer prevention strategies include the use of cytology-based testing (Pap 
testing) as a primary screening tool, with the addition of HPV testing to increase screening sensitivity for 
the detection of CIN2+ among women 30 years and older, as well as primary hrHPV screening. Although 
hrHPV testing is more sensitive than liquid-based cytology to detect high-grade (CIN2+), it is not as 
predictive of disease course among women with low-grade CIN (CIN1)[77]. A relatively small proportion 
of CIN1 cases progress to CIN2+, while most CIN1 cases regress to normal epithelia[78]. Follow-up of 
low-grade CIN is still recommended in the US until regression to normal colposcopic impression or 
negative cytology, leading to a high burden of cost and decreased clinical visit adherence[1, 60]. 
Therefore, it would be advantageous to identify novel biomarkers that can differentiate CIN1 cases which 
progress from CIN1 cases which regress. 
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Epigenetic profiles have been hypothesized as potential diagnostic biomarkers for susceptibility 
to cervical cancer [79, 80]. Modifications of the epigenome include DNA methylation at cytosine-guanine 
dinucleotide sequences (CpG sites) which can affect the expression of genes involved in cancer 
tumorigenesis [26]. Genomic imprinting involves inheritance of parent-of-origin specific epigenetic 
modifications controlling allele specific gene expression[26, 80]. Imprinted genes often exist in clusters 
and are regulated by imprinting centers, which can include differentially methylated regions (DMRs) that 
are rich in CpG sites[26].  
Loss of imprinting (LOI) due to aberrant methylation at DMRs has been linked to various growth 
and developmental disorders[81], including Beckwith-Wiedemann Syndrome (BWS)[82]. In case-control 
studies, differential methylation of targeted imprinted genes has been associated with cancer outcomes, 
such as Wilms’ Tumor of the kidney[83], breast cancer[84, 85], colorectal cancer[79, 86, 87], and 
prostate cancer[88]. Preliminary analyses have also found dysregulated expression of imprinted genes 
involved in tumor suppression (e.g. HYMAI, PEG3, PLAGL1, MEST, CDKN1C) in cervical cancer 
specimens compared to normal cervical tissue [89]. Studies have examined the influence of methylation 
patterns on the expression of HPV E6/E7 oncogenic proteins which deactivate host cell tumor suppressor 
p53 and thus may promote cervical carcinogenesis [31, 46]. The influence of host aberrant methylation at 
imprinted gene control regions on the natural history of low-grade CIN has not been assessed.  
It is important to establish molecular-based methods of differentiating CIN1 cases which progress 
versus regress in order to improve clinical management. The current study examines whether aberrant 
DNA methylation patterns of imprinted genes influence regression of low-grade CIN in the Cervical 
Intraepithelial Neoplasia Cohort Study (CINCS). 
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Figure 5. 1 CINCS Study Flowchart  
 
 
 
Participants with measured HPV genotypes and DMR methylation data were comparable to those of the 
entire cohort not included in this analysis. 
Methods 
Study population 
From June 2010 – April 2014, women attending ten Duke University hospitals and clinics in 
Durham, North Carolina were invited to participate in CINCS, as previously described [62]. Briefly, all 
clinics used Duke-affiliated pathology laboratories for cytology and histological evaluation. The CINCS 
cohort is comprised of 1303 women who were referred for a colposcopy following an abnormal liquid-
based cytology result. Participants were eligible if they provided written consent, were new visitors to the 
clinic, 21-79 years old, English or Spanish speakers, and able to give informed consent. We excluded 
women who had received previous treatment for cervical lesions—cold knife conization (CKC), 
electrosurgical excision procedure (LEEP), cryotherapy, or hysterectomy; had moved out of the study 
area; or did not intend to receive follow-up care at one of the 10 Duke clinics. Women who were 
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diagnosed with CIN1 at enrollment and had at least one follow-up visit were included in the present 
statistical analyses. Approval for this study was granted by the Institutional Review Boards at Duke 
University (Durham, NC, USA), North Carolina State University (Raleigh, NC, USA) and University of 
North Carolina (Chapel Hill, NC, USA). 
 
Data collection and laboratory analyses 
At enrollment, participants had a physician-directed cervical examination with a colposcopy-
directed biopsy. Women diagnosed with CIN1 by colposcopic impression without biopsy (n=29) at 
enrollment were also included in the study, as prevalence of hrHPV was comparable to the hrHPV 
prevalence among those who underwent a biopsy. Study participants attended a clinical visit 
approximately every 6 months for the first two years, and every 12 months for final third year, following 
clinical practice guidelines for management of CIN. During each follow-up visit, all women underwent a 
liquid-based cytology (LBC) test. For participants with abnormal cytology results, clinic physicians 
performed colposcopy examination if necessary. Directed biopsies at follow-up colposcopy visits 
occurred only if clinically necessary, according to physician’s best judgement and per clinical guidelines 
for management of precancerous cervical lesions[1]. Study staff administered a questionnaire to ascertain 
information on any behavioral and clinical characteristics at enrollment and follow-up visits, including 
age, race/ethnicity, current smoking status, history of oral contraceptive use and parity - risk factors for 
CIN and cervical cancer. 
 
Ascertainment of Cervical Cytology and Histology 
To conduct a LBC test, the clinic physician utilized a spatula and cytobrush to obtain exfoliated 
cervical cells. Cervical specimens were suspended in a ThinPrep® vial containing proprietary fluid with 
at least 50% methanol (Cytyc®, Malborough, MA, USA) for cytological assessment. All study clinic 
pathologists evaluated LBC cytology according to Bethesda criteria[48]. The residual LBC cervical 
exfoliated cell specimens were stored at 4°C prior to HPV DNA testing. 
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Biopsy results were also reviewed and graded for severity by a pathologist at DUPL. All 
histological biopsy specimens were tested for adequacy using the 2012 American Society for Colposcopy 
and Cervical Pathology (ASCCP) guidelines. Information on cytology and histology were abstracted from 
patient medical records.  
 
HPV Testing and Typology 
HPV typology was assessed using cervical exfoliated cells from the enrollment pelvic exam. 
ThinPrep® specimens were collected during the same enrollment visit and sent to the Johns Hopkins 
University and the University of Hawaii Cancer Center for laboratory testing, as previously described [49, 
50]. Following DNA extraction, HPV status was determined by targeted amplification of a 450bp region 
of the HPV L1 genome using PGMY09/PGMY11 primers [49, 50] amplify. Amplification of the human 
β-globin gene was included as an internal control for sample sufficiency. Specimens identified as HPV-
positive were subsequently genotyped using the HPV Linear Array® (Roche Diagnostics, Branchburg, 
NJ, USA). This assay is designed to detect 13 high-risk HPV types and 27 low-risk HPV types.  
 
Assessment of DNA Methylation in Imprinted Differentially Methylated Regions (DMRs) 
Nucleic acid extraction 
DNA and RNA was extracted from the LBC cell pellet using a protocol for simultaneous nucleic 
acid extraction provided by Teltest (Friendswood, TX) for their RNA Stat60 and DNA Stat60 reagents. 
Nucleic acids were aliquoted, barcoded, and stored at -80ºC until required.  
 
DNA methylation analysis 
 DNA methylation was measured using genomic DNA at differentially methylated regions 
(DMRs) regulating genomic imprinting of IGF2/H19, IGF2, PEG1/MEST, Kv DMR, DLK1/MEG3, 
PLAGL1/HYMAI, PEG10 and PEG3 imprinted domains, using Sequenom (San Diego, CA) MassARRAY 
EpiTYPER assays. Bisulfite-treated DNA was processed using the EZ-96 DNA Methylation Kit (Zymo 
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Research Corporation, Irvine, CA) to convert unmethylated DNA cytosine bases to uracil bases, leaving 
methylated cytosines unchanged using per manufacturer’s protocol. We used Sequenom (San Diego, CA) 
EpiDesigner software to design primers complementary to bisulfite-converted DNA in regions without 
CpG nucleotides, adding a T7 promoter site to all forward primers. Polymerase chain reaction (PCR) 
assays were performed on the treated DNA samples using HotStarTaq DNA Polymerase (Qiagen, Hilden, 
Germany). PCR products were treated with Shrimp alkaline phosphatase (SAP, Sequenom, San Diego, 
CA) followed by transcription and T cleavage reactions according to the protocol. Cleanup and 
sequencing were performed according to the EpiTYPER user guide. Matrix-assisted laser 
desorption/ionization and time-of-flight mass (MALDI-TOF) spectrometry analysis was performed on 
resulting transcripts using the MassARRAY system (Sequenom). Fragments generated from the PCR 
assay differed by size and mass, allowing for quantification of methylated forms of each targeted 
fragment. 
 
Statistical analyses 
Methylation percentage was calculated at each CpG site of each imprinted gene DMR. Because 
imprinted gene DMRs are characterized by having one fully methylated allele and one unmethylated 
allele, the expected value of methylation for an imprinted gene in a diploid cell is approximately 50%. A 
total of 8 imprinted DMRs were analyzed with 5 CpG sites for the IGF2/H19 DMR; 10 CpGs for the 
IGF2AS DMR; 31 CpGs for the MEST/MESTIT1 DMR; 27 CpG sites for the Kv DMR; 31 CpG sites for 
the DLK1/MEG3 DMR; 8 CpG sites for the PLAGL1/HYMAI DMR; 11 CpG sites for the PEG10 DMR; 
and 12 CpG sites for the PEG3 DMR. Genomic coordinates for each DMR have been previously 
published [90]. CpG sites with greater than 10% missing data at single CpG sites were excluded. As a 
result, DMRs in the analysis included IGF2AS, DLK1/MEG3, PEG10 and the Kv DMR. Median 
percentages were calculated across DMRs. 
Regression of cervical lesions was defined as a diagnosis of negative/normal cytology (or 
histology if applicable) at two consecutive follow-up visits. Per conservative clinical practice, cytology 
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results were utilized to determine regression status if the participants had missing histology data. 
Persistence was defined as a diagnosis of low-grade histology (CIN1) at follow-up or low-grade lesions 
during cytology testing (e.g. low-grade squamous epithelial lesions (LSIL), or atypical squamous cells of 
undetermined significance (ASC-US)). Progression was defined as a follow-up histologic diagnosis of 
CIN2+, or as a cytological diagnosis of high-grade squamous epithelial lesions (HSIL), LSIL-H (LSIL, 
cannot exclude HSIL), or ASC-H (ASC, cannot exclude HSIL). Women with a negative/normal screening 
at one follow-up time point were not considered to have regressed for the main study analyses. For 
women who received treatment (LEEP, CKC, cryotherapy, or hysterectomy) at a follow-up visit, the 
histological diagnosis from the pre-treatment specimen was utilized.  
A univariate analysis was performed to assess the distribution of methylation biomarkers and 
covariates. Kaplan-Meier product-limit method was used to estimate the cumulative proportion of CIN1 
regression, stratified by median methylation percentage at each DMR. The Log-rank test was used to 
assess differences between regression probabilities over time at methylation percentages below and above 
the median for each DMR (Figures 5.2.1-5.2.4). Cox proportional hazards regression models were 
employed to estimate unadjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for the 
association between methylation at a specific CpG site and CIN1 regression. Time-to-regression was 
measured from the date of enrollment to the date of the second consecutive negative/normal histological 
or cytological diagnosis. Participants contributed person-time to the longitudinal analyses up to the 
occurrence of regression or the date of the last attended clinical study visit. Participants who received 
treatment during the study were right censored at the date of procedure. Administrative censoring 
occurred at 3 years. Woman-months was calculated as the sum of person-time for all women at risk 
among the specific methylation exposure group. 
We calculated a median methylation percentage to represent a summary measure of methylation 
across each candidate region (when applicable) to estimate HRs and 95% CIs in the univariate and 
multivariate Cox regression models. In the Cox models, methylation levels (treated as a continuous 
variable) were rescaled using the interquartile range (IQR) for each CpG site or the IQR for median 
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methylation across the gene DMR. Confounders selected for the multivariable Cox regression model were 
determined a priori using conceptual models (directed acyclic graphs). Covariates considered for the 
analyses included continuous age at enrollment, hrHPV infection at enrollment, race/ethnicity, current 
smoking status at enrollment (current vs. non-current), history of oral contraceptive use (ever vs. never), 
and parity (continuous). Covariate modification was assessed using Akaike Information Criteria (AIC) for 
model fit. A sensitivity analysis was conducted to determine the change in estimate given a regression 
event at only one time point (Table 5.4). Further sensitivity analyses were also conducted to determine the 
impact of drop outs; CIN1 regression at a single follow-up visit; exclusion of women who were hrHPV 
negative at enrollment; and the exclusion of women who had high grade cytology (HSIL or higher) at 
their enrollment pap (preceding the enrollment colposcopy). All statistical analyses were conducted using 
SAS version 9.4 (SAS Institute, Cary, NC). 
A total of 486 women of the 1303 enrolled CINCS participants had both methylation and HPV 
DNA laboratory results. Of these, 15 women with no CIN diagnosis, 230 women with a negative/normal 
histological diagnosis at enrollment, and 75 women with CIN2+ histological diagnosis were excluded. 
The remaining 164 CIN1 cases at enrollment were included in analyses. 
 
Results 
Median age of CIN1 cases at enrollment (n=164) was 26.6 (range: 21-64.4 years) (Table 5.1). 
Nearly half of participants were non-Hispanic White (47%), while over one-third were Black (39%). Only 
11% of participating women were current smokers, whereas most had a history of oral contraceptive use 
(78%). Over 80% of participants had infection with any hrHPV type; 16% were infected with HPV16 or 
HPV18, and <1% had infection with both HPV16 and HPV18. 
Median DMR methylation levels were 58% for IGF2AS; 29% for Kv DMR, 52% for MEG3, and 
32% for PEG10 (Table 5.2). Within the Kv and PEG10 DMRs, there was ≤30% methylation at most CpG 
sites. There was little variation in Kv DMR methylation (DMR IQR = 0.07) and in PEG10 methylation 
(DMR IQR = 0.07) among women with CIN1. 
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Median study follow-up time was 10.5 months (SD: 6.9; range: 0.9-30.8). Thirteen women 
(8.5%) dropped out after enrollment. No differences were observed between those who dropped out 
(n=13) compared to those who had at least one follow-up visit (n=151). Over the 3-year study duration, a 
total of 53 (35.1%) women regressed from CIN1, compared to 98 (64.9%) who did not regress (37 
women who regressed at only one visit, 41 women with persistent CIN1 and 20 women progressed to 
CIN2+). Median time to CIN1 regression was 12.6 months (range: 4.5-24.0 months). Fewer than half of 
follow-up diagnoses assessed for the longitudinal analysis were defined by cytology, as cases with normal 
or low-grade cytology at their follow-up visit did not warrant a biopsy (43% cytology-based follow-up 
diagnoses vs. 57% colposcopy/biopsy-based follow-up diagnoses). 
The unadjusted estimated cumulative probability of regression plots showed that women with 
methylation percentages above the median at IGF2AS CpG 5 and at the PEG10 DMR had lower 
incidence of regression over a 3-year period compared to women with methylation percentages below the 
median (Figures 5.2.1-5.2.4). No notable differences were observed in CIN1 regression probability at the 
Kv and MEG3 DMRs (Figures 5.2.2-5.2.3). 
There was at least a 40% decrease in the probability of CIN1 regression for women with higher 
methylation compared to women with lower methylation at IGF2AS CpG 5 (unadjusted HR, 0.57; 95% 
CI: 0.34, 0.794; p=0.03; Table 5.3). At the PEG10 DMR, women with higher methylation had a 21% 
decrease in likelihood of CIN1 regression (unadjusted HR, 0.79; 95% CI: 0.65-0.97; p=0.02). After 
adjusting for continuous age, hrHPV status, race, current smoking status, continuous parity and history of 
oral contraceptive use, the probability of CIN1 regression decreased by 58% for women with higher 
methylation at IGF2AS CpG 5 compared to those with lower methylation (adjusted HR or aHR, 0.42; 
95% CI, 0.23-0.77; p=0.005). Within the PEG10 DMR, the likelihood of CIN1 regression decreased by 
22% for women who had higher methylation compared to women with lower methylation (aHR: 0.78, 
95% CI, 0.63-0.96, p=0.02). Evidence for modification by a covariate was not observed in data analyses. 
A sensitivity analysis was conducted to consider time to CIN1 regression at a single follow-up visit and 
found that increased methylation at both PEG10 and IGF2AS DMRs remained associated with a 
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decreased probability of CIN1 regression (Table 5.4). Additionally, an increase in methylation at Kv 
DMR resulted in a 28% decrease in the probability of first CIN1 regression (aHR: 0.72; 95% CI, 0.56-
0.93; p=0.01). Exclusion of either hrHPV-negative participants or participants with high grade cervical 
cytology at their enrollment Pap test did not significantly change adjusted hazard ratio estimates (data not 
shown) 
Discussion 
This longitudinal study of 164 CIN1 patients is among the first to prospectively examine aberrant 
methylation patterns of regulatory regions of imprinted genes and their association with low-grade CIN 
regression. The 3-year cumulative probability of CIN1 regression was lower among women with higher 
levels of methylation compared to women with lower levels of methylation at the PEG10 DMR and the 
IGF2AS DMR CpG 5. Higher methylation levels at the IGF2AS and PEG10 DMRs decreased the 
likelihood of CIN1 regression. A decrease in the probability of CIN1 regression due to increased 
methylation at Kv DMR was also observed over one follow-up visit. These findings may implicate these 
DMRs as potential epigenetic biomarkers of regression in low-grade CIN cases.  
Abnormal methylation of IGF2 may be associated with mechanism involved in cervical 
tumorigenesis. Though a notable association was found between aberrant methylation at IGF2AS CpG 5, 
conclusions from this data regarding the entire regulatory IGF2AS region could not be made. Aberrant 
DNA methylation of the IGF2 and PEG10 DMRs and other sequences regulating imprinted genes have 
been previously associated with higher risk of cervical dysplasia and invasive cancer in cross-sectional 
studies [91-94]. Hypomethylation at the IGF2 DMR was associated with an increased risk of invasive 
cervical carcinoma in a case-control study conducted in Tanzania [93]. IGF2AS is a paternally expressed 
component of a downstream imprinted center, IC1 (located on human chromosome 11p15.5) that 
promotes cell proliferation[95].  
Paternally-expressed PEG10 also appears to have a role in cell proliferation [96, 97]. 
Overexpression of PEG10 was associated with poor outcomes in hepatocellular carcinoma [96] and 
  54
increased proliferation of breast cancer cells in culture [97]. These findings warrant additional research 
into the relationship between PEG10 methylation and expression in CIN/ICC tissues in a larger cohort, as 
well as further investigation into other epigenetic changes (e.g. chromatin modifications) that may be 
associated with imprinted gene deregulation in cervical cancer development. 
 Interestingly, when estimating time-to-regression at a single follow-up visit, increased 
methylation at the Kv DMR also decreased the probability of regression relative to women who had lower 
levels of methylation. The Kv DMR is maternally methylated, compromised of the imprint control region 
IC2, located at Chr11p15.5, which regulates at least 11 imprinted genes [98]. Imprinting at this region 
controls transcription of the long non-coding RNA KCNQ1OT1, which regulates the expression of cyclin-
dependent kinase inhibitor 1C gene (CDKN1C), an inhibitor protein involved in cell proliferation and 
growth regulation [99]. While studies on Kv DMR in the context of cervical dysplasia and ICC are 
limited, changes in methylation at Kv DMR/IC2 have been positively associated with colorectal cancer 
[87] and breast cancer [84]. 
Infection with hrHPV may influence methylation patterns in imprinted genes. Aberrant 
methylation of imprinted genes has been associated with a higher risk of hrHPV infection and may serve 
as an intermediate in the natural history of CIN1, as seen in previous studies [93, 94]. Differential 
methylation of DMRs associated with PEG3, PEG1/MEST and IGF2 expression was strongly associated 
with HPV infection among women with ICC [93, 94]. Imprinted tumor suppressor CDKN1C was 
upregulated during E2 (HPV viral regulatory protein)-mediated HeLa cell senescence and concomitant 
repression of E6/E7 HPV viral oncogenes [100]. These findings implicate downregulation of CDKN1C, 
leading to upregulated cervical cell proliferation and subsequent cervical tumor development [100]. 
Inhibition of cell apoptosis due to loss of E2 expression in cervical carcinogenesis may be mediated in 
part by aberrant methylation and subsequent deregulation of pivotal genes, some of which are imprinted 
and implicated in cervical cancer development pathways [93, 100]. 
A major advantage of this study was the ability to prospectively assess the association between 
methylation markers and CIN. Accounting for time in estimating the probability of CIN1 regression 
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improves the strength of the association. The findings here, comparable to previous studies, further 
support the consideration of imprinted gene biomarkers as a screening tool for LSIL/CIN1 cases [93, 94].  
Among potential limitations, this study did not assess HPV infection at study follow-up, which 
would have allowed for a more stringent definition of cervical lesion regression, including HPV negative 
status in addition to histological/cytological outcomes. However, the decision to define the regression as 
two consecutive negative screening results, rather than one, strengthened the robustness of this study. 
Future work should include capturing HPV infection status and HPV typing at all follow-up visits to 
determine the extent to which persistent hrHPV infection plays a role in the association between 
methylation patterns and the course of cervical dysplasia. Previous research has suggested that HPV-
infection and cervical cell proliferation may be related to downregulation of CDKN1C, a tumor 
suppressor gene involved in cell proliferation and growth regulation controlled by IC2/Kv DMR [100]. 
The current study was also limited by the possibility that women with CIN1 at enrollment may have been 
misclassified. To address this, a sensitivity analysis was conducted by excluding women with high-grade 
cervical cytology at enrollment, producing similar results. The 2012 ASCCP guideline update [1] likely 
influenced loss to follow-up as well as created variability in the number of visits and duration between 
follow-up visits for each participant. Obtaining data on changes in smoking habits and other time-
dependent behavioral/lifestyle factors also would broaden future research in order to investigate their 
influence on methylation patterns among women with cervical disease [101]. The incorporation of 
RNA/gene expression data would further characterize the impact of aberrant methylation among women 
with and without disease. 
These study findings indicate further investigation into IGF2 and PEG10 DMRs as a diagnostic 
biomarker in women with low-grade CIN is warranted. It is critical to understand risk factors that 
determine the natural course of CIN in order to improve the effectiveness of current cervical cancer 
screening methods. Characterization of potential cervical tumorigenesis pathways related to the 
dysregulation of imprinted gene networks would help to establish novel epigenetic biomarkers in CIN 
management to reduce cervical cancer incidence.  
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Tables and Figures 
Table 5. 1 Characteristics of 164 Women with CIN1 at enrollment in the CINCS Study*  
Enrollment characteristic N 
 
(Range)% 
   
Age (years)   
Median 26.6 (21.0-64.4) 
18-24 65 39.6 
25-29 56 34.2 
30-34 13 7.9 
35+ 30 18.3 
High-Risk HPV†   
Negative 32 19.5 
Positive 132 80.5 
HPV 16/18   
Negative 138 84.2 
Positive 26 15.9 
Race   
Non-Hispanic White 77 47.0 
Black/African-American 64 39.0 
Other‡ 23 14.0 
Current Smoker   
No 146 89.0 
Yes 18 11.0 
Ever Use of Oral 
Contraceptives§ 
  
No 33 21.7 
Yes 119 78.3 
Parity§   
Nulliparous 93 57.4 
Primiparous (1) 29 17.9 
Multiparous (2+) 40 24.7 
* CIN = Cervical Intraepithelial Neoplasia; CINCS = Cervical Intraepithelial Neoplasia Cohort Study 
† Includes high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 
‡ Other includes Hispanic/Asian/Pacific Islander/Native American/Multiracial 
§ Numbers do not add up to the total sample size due to missing data
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Table 5. 2 Imprinted gene DMR§ methylation distributions in 164 CIN1 patients at enrollment* 
Gene 
Name CpG site N† Mean Median SD‡ 
Interquartile 
Range Range 
IGF2AS 5 157 0.47 0.58 0.32 0.57 (0.00, 0.96) 
Kv        
 DMR§ 144 0.30 0.29 0.05 0.07 (0.16, 0.42) 
 1 143 0.25 0.26 0.06 0.07 (0.12, 0.39) 
 6 144 0.25 0.26 0.06 0.08 (0.08, 0.41) 
 8,9 144 0.27 0.27 0.05 0.07 (0.03, 0.40) 
 10,11,12 142 0.23 0.23 0.06 0.07 (0.03, 0.38) 
 15 144 0.30 0.31 0.06 0.08 (0.14, 0.43) 
 17,18 144 0.30 0.31 0.05 0.07 (0.14, 0.49) 
 20 144 0.31 0.31 0.06 0.06 (0.10, 0.47) 
 21 144 0.30 0.30 0.06 0.05 (0.12, 0.47) 
 22 144 0.24 0.24 0.04 0.04 (0.12, 0.43) 
 24 144 0.29 0.30 0.08 0.10 (0.11, 0.44) 
 26,27 144 0.55 0.55 0.06 0.07 (0.35, 0.70) 
MEG3||        
 DMR§ 152 0.49 0.52 0.11 0.19 (0.26, 0.82) 
 3 152 0.57 0.59 0.16 0.17 (0.11, 1.00) 
 6 150 0.54 0.54 0.09 0.28 (0.31, 0.96) 
 15 152 0.40 0.39 0.10 0.14 (0.00, 0.80) 
 16 150 0.38 0.38 0.10 0.15 (0.00, 0.82) 
 20,21 150 0.43 0.42 0.09 0.14 (0.05, 0.75) 
 22 150 0.54 0.54 0.09 0.17 (0.31, 0.96) 
 23 152 0.46 0.46 0.10 0.14 (0.21, 0.95) 
 26,27,28 152 0.55 0.55 0.11 0.21 (0.03, 0.89) 
 29,30,31 152 0.57 0.56 0.12 0.19 (0.12, 1.00) 
PEG10        
 DMR§ 140 0.30 0.32 0.08 0.07 (0.00, 0.45) 
 5 137 0.31 0.32 0.10 0.07 (0.02, 0.83) 
 6 138 0.26 0.27 0.12 0.14 (0.00, 0.47) 
 7 139 0.32 0.34 0.10 0.07 (0.00, 0.85) 
* CIN = Cervical Intraepithelial Neoplasia; CINCS = Cervical Intraepithelial Neoplasia Cohort Study 
† Numbers do not add up to the total sample size due to missing data 
‡ SD = Standard Deviation 
§ DMR = Differentially methylated region; median across all CpG loci for candidate gene 
|| MEG3 intronic differentially methylated region
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Table 5. 3 Analysis of CIN1 regression by imprinted gene DMR||/CpG site among CINCS participants* 
Gene Name CpG Site 
Woman-
Months 
Regression 
Events (N)† 
Unadjusted HR‡ 
(95% CI) p-value 
Adjusted HR 
(95% CI) ‡§ p-value 
IGF2AS 5 2742 53 0.57 (0.34, 0.94) 0.03 0.42 (0.23, 0.77) 0.005 
Kv        
 DMR|| 2514 49 0.81 (0.55, 1.19) 0.28 0.84 (0.57, 1.28) 0.42 
 1 2485 48 0.78 (0.54, 1.14) 0.20 -- -- 
 6 2514 49 0.75 (0.50, 1.12) 0.15 -- -- 
 8,9 2514 49 1.06 (0.74, 1.50) 0.75 -- -- 
 10,11,12 2473 48 0.92 (0.64, 1.30) 0.63 -- -- 
 15 2514 49 0.73 (0.51, 1.05) 0.09 -- -- 
 17,18 2514 49 0.87 (0.59, 1.27) 0.46 -- -- 
 20 2514 49 0.89 (0.67, 1.17) 0.39 -- -- 
 21 2514 49 0.89 (0.66, 1.19) 0.62 -- -- 
 22 2514 49 1.02 (0.76, 1.37) 0.90 -- -- 
 24 2514 49 0.70 (0.45, 0.99) 0.04 -- -- 
 26,27 2514 49 1.10 (0.80, 1.53) 0.55 -- -- 
MEG3¶        
 DMR|| 2762 53 0.80 (0.52, 1.21) 0.28 0.82 (0.53, 1.27) 0.37 
 3 2762 53 0.88 (0.58, 1.33) 0.54 -- -- 
 6 2720 53 0.90 (0.61, 1.35) 0.61 -- -- 
 15 2762 53 0.67 (0.49, 0.91) 0.01 -- -- 
 16 2741 52 0.76 (0.54, 1.06) 0.10 -- -- 
 20,21 2725 52 0.75 (0.54, 1.03) 0.07 -- -- 
 22 2720 53 0.90 (0.60, 1.35) 0.61 -- -- 
 23 2762 53 0.92 (0.68, 1.25) 0.60 -- -- 
 26,27,28 2762 53 0.78 (0.53, 1.15) 0.21 -- -- 
 29,30,31 2762 53 0.85 (0.57, 1.28) 0.44 -- -- 
PEG10        
 DMR|| 2517 50 0.79 (0.65, 0.97) 0.02 0.78 (0.63, 0.96) 0.02 
 5 2461 49 0.57 (0.42, 0.78) <0.001 -- -- 
 6 2475 50 0.66 (0.47, 0.92) 0.02 -- -- 
 7 2510 50 0.85 (0.69, 1.05) 0.12 -- -- 
* CIN = cervical intraepithelial neoplasia; CINCS = Cervical Intraepithelial Neoplasia Cohort Study; cases with at least one follow-up visit 
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† Regression event defined as histology- or cytology-negative diagnosis over two consecutive follow-up visits 
‡ HR= Hazard ratio; 95% CI= 95% confidence intervals; continuous methylation levels rescaled using interquartile range for each CpG site  
§ Adjusted for continuous age, high risk-HPV, race, smoking, continuous parity and history of oral contraceptive use  
|| DMR = differentially methylated region (median methylation of all CpG sites)  
¶ MEG3 intronic differentially methylated region 
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Table 5. 4 Sensitivity analysis: CIN1 regression by imprinted gene using one regression time-point* 
Gene Name CpG Site 
Woman-
Months 
Number of 
Events 
Unadjusted HR† 
(95% CI) p-value 
Adjusted HR 
(95% CI) †‡ p-value 
IGF2AS 
5 1406 92 0.63 (0.42, 0.95) 0.03 0.46 (0.28, 0.75) 0.002 
Kv        
 DMR§ 1323 85 0.71 (0.53, 0.95) 0.02 0.65 (0.47, 0.92) 0.01 
MEG3¶        
 DMR§ 1410 93 0.95 (0.68, 1.32) 0.74 1.04 (0.72, 1.49) 0.88 
PEG10        
 DMR§ 1253 84 0.84 (0.71, 0.99) 0.03 0.82 (0.69, 0.97) 0.02 
* CIN=cervical intraepithelial neoplasia; 151 cases with at least one follow-up visit 
† HR=Hazard ratio; 95% CI= 95% confidence intervals; continuous methylation levels rescaled using interquartile range for each CpG site 
‡ Adjusted for high-risk type human papillomavirus infection, race, current smoking, continuous parity and history of oral contraceptive use 
§ DMR = differentially methylated region (median of all CpG sites) 
|| MEG3 intronic differentially methylated region  
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Figure 5.2. 1 Time to CIN1 regression for IGF2AS (at CpG 5), stratified at median methylation percentage* 
 
*CIN = cervical intraepithelial neoplasia 
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Figure 5.2. 2 Time to CIN1 regression for Kv DMR, stratified at median methylation percentage* 
 
* CIN = cervical intraepithelial neoplasia; DMR = differentially methylated region (median methylation of all CpG sites)  
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Figure 5.2. 3 Time to CIN1 regression, stratified at median MEG3 DMR methylation percentage* 
 
* CIN = cervical intraepithelial neoplasia; DMR = differentially methylated region (median methylation of all CpG sites)   
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Figure 5.2. 4 Time to CIN1 regression, stratified at median PEG10 DMR methylation percentage* 
 
* CIN = cervical intraepithelial neoplasia; DMR = differentially methylated region (median methylation of all CpG sites)
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CHAPTER SIX: DISCUSSION 
 
Overview 
This dissertation aimed to examine biological markers associated with the natural history of CIN in 
a cohort of women in North Carolina in order to better characterize CIN for clinical management and 
improve cervical cancer prevention strategies. Detection of hrHPV, as well as aberrant methylation, may 
be used for triage to colposcopy among HPV-screen positive women for CIN.  
 
Summary of Findings 
The first aim of this dissertation was to examine the epidemiology of HPV infection among 
CINCS women and to assess the association between individual and collective HPV genotypes and 
progression of CIN2+ over a 3-year period. We found that hrHPV prevalence among this population was 
highest among types 66, 51 and 16 among unvaccinated women with multiple infections and in types 16, 
52 and 35 in single infection. These prevalence estimates differed from vaccinated CINCS participants, 
where hrHPV genotypes 66, 39, and 51 occurred most frequently in multiple infections and genotypes 51, 
66, 52/58 in single infections. Considering these prevalence estimates, we found that the highest 
incidence rates of CIN2+ among with women without prior vaccination occurred in hrHPV genotypes 
16/33/51 in multiple, and genotypes 66, 31, and 51 in single infections. Among vaccinated women, 
hrHPV genotypes 33, 31, and 45 had the highest CIN2+ incidence rates in multiple infections, with 
genotypes 31, 39 and 16 for single infections. As expected, we found that hrHPV-16, was associated with 
a 3-fold increased risk of progression over 3 years. Interestingly, hrHPV-51 was also associated with a 3-
fold increase of progression in the CINCS study. The implication of genotype 51 was unexpected, as 
  66
other studies on hrHPV risk attribution of CIN2/3+ have identified other alpha-9 viruses such as 18, 31 
and 45.  
The second aim of this dissertation was to examine the association between aberrant methylation 
of imprinted genes and CIN1 regression. The 3-year cumulative probability of CIN1 regression was lower 
among women with higher levels of methylation compared to women with lower levels of methylation at 
the PEG10 DMR and the IGF2AS DMR CpG 5. Higher methylation levels at the IGF2AS and PEG10 
DMRs decreased the likelihood of CIN1 regression. A decrease in the probability of CIN1 regression due 
to increased methylation at Kv DMR was also observed over one follow-up visit. These findings may 
implicate PEG10 and IGF2AS DMRs as potential epigenetic biomarkers of regression in low-grade CIN 
cases.  
 
Public Health Significance 
The findings of this research addresses gaps in the literature related to cervical precancer screening 
and CIN management. The data provide an increased understanding of the epidemiology of HPV 
genotypes in high-grade CIN progression. With the addition of hrHPV types in screening, women who 
are hrHPV-positive but cytology-negative may be further differentiated for triage to colposcopy. 
Preventive strategies for CIN, such as the HPV vaccine, will benefit from increased knowledge of 
individual and composite risk attribution of HPV genotypes to CIN progression, especially given the 
effect of the current vaccines on HPV prevalence in the population. The use of DNA methylation in 
relation to imprinted genes and loss of imprinting, though a novel area of study, may provide an 
additional biomarker (similar to p16) in identifying high-risk cases and low-risk cases during screening. 
With both HPV and DNA methylation of imprinted genes, there are great implications for cervical 
screening practices and clinical management in the US. These findings, if replicated, could encourage the 
continual evolution of ASCCP guidelines and new screening criteria for clinical screening and 
management guidelines. Successful characterization and implementation of these two biological factors in 
the natural history of CIN would create a new template for clinical management practice of CIN and 
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cervical cancer prevention in the US, ultimately promoting the reduction of cervical cancer incidence 
globally.  
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APPENDIX 
A1. Risk of progression to CIN2+* by race/ethnicity by HPV† type‡ in 364 unvaccinated CINCS* patients 
 Adjusted HR (95% CI)§ 
HPV† Genotype Non-Hispanic White Black Other 
High-Risk    
16 4.3 (1.5, 12.7) ¶  1.8 (0.4, 8.3) 0.8 (0.1, 7.8) 
51 1.7 (0.4, 7.9) 2.9 (1.02, 8.1) ¶ -- 
* CINCS = Cervical Intraepithelial Neoplasia Cohort Study; CIN = cervical intraepithelial neoplasia; 
CIN2+ event = CIN2+ diagnosis at follow-up given colposcopy-confirmed negative or CIN1 diagnosis at 
enrollment 
† HPV = Human papillomavirus 
‡ Includes single and multiple type infections 
§ HR = hazard ratio; 95% CI = 95% confidence interval. Elastic net Cox regression model parameter 
specifications: α=0.012, λ = 1.7. Adjusted for the other covariates in the model. 
¶ p<0.05 
 
 
 
A2. Risk of progression to CIN2+* by race/ethnicity among single HPV† type infections in 152 
unvaccinated CINCS* patients 
HPV† Genotype 
Adjusted HR (95% CI)‡ 
Non-Hispanic White  Black Other 
High-Risk    
16 4.3 (1.5, 12.7)§ 1.8 (0.4, 8.3) 0.8 (0.1, 7.8) 
51 1.7 (0.4, 7.9) 2.9 (1.02, 8.1)§ -- 
* CINCS = Cervical Intraepithelial Neoplasia Cohort Study; CIN = cervical intraepithelial neoplasia 
† HPV = Human papillomavirus 
‡ HR = hazard ratio; 95% CI = 95% confidence interval. Elastic net Cox regression model parameter 
specifications: α=0.012, λ = 1.7. Adjusted for the other covariates in the model. 
§ p<0.05 
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